

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

A Synergistic Effect of Retinopathy and Chronic Kidney Disease on Long-term Mortality in Type 2 Diabetic Inpatients with Normal Urinary Albumin or Protein: A Retrospective Cohort Study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-021655
Article Type:	Research
Date Submitted by the Author:	13-Jan-2018
Complete List of Authors:	Li, Yu-Hsuan; Taichung Veterans General Hospital, Division of Endocrinology and Metabolism, Department of Internal Medicine; Sheu, Wayne; Taichung Veterans General Hospital, Superintendent Lee, I-Te; Taichung Veterans General Hospital, Division of Endocrinology and Metabolism, Department of Internal Medicine
Keywords:	Diabetic nephropathy & vascular disease < DIABETES & ENDOCRINOLOGY, Diabetic retinopathy < DIABETES & ENDOCRINOLOGY, Diabetes & endocrinology < INTERNAL MEDICINE

SCHOLARONE™
Manuscripts

Peer Review Only

1
2
3 **A Synergistic Effect of Retinopathy and Chronic Kidney Disease on Long-term**
4 **Mortality in Type 2 Diabetic Inpatients with Normal Urinary Albumin or Protein: A**
5 **Retrospective Cohort Study**
6
7
8
9

10
11 Yu-Hsuan Li ¹, Wayne H-H Sheu ^{1,2}, I-Te Lee ^{1,2,3,*}
12
13

14
15
16 ¹Division of Endocrinology and Metabolism, Department of Internal Medicine, Taichung
17 Veterans General Hospital, Taichung, Taiwan
18

19
20 ² School of Medicine, National Yang-Ming University, Taipei, Taiwan
21

22 ³ School of Medicine, Chung Shan Medical University, Taichung, Taiwan
23
24
25
26

27 **Running title:** DR and CKD in DM with Normoalbuminuria
28
29
30
31

32 ***Correspondence:** I-Te Lee, MD, PhD,
33
34

35 No. 1650 Taiwan Boulevard, Sect. 4, Taichung 40705, Taiwan.
36
37

38 Tel: +886-4-23741300, Fax: +886-4-23741318, E-mail: itlee@vghtc.gov.tw
39
40
41
42

43 ***Correspondence and reprint to:** I-Te Lee MD, PhD. No. 1650 Taiwan Boulevard, Sect. 4,
44 Taichung 40705, Taiwan.
45
46

47 E-mail: itlee@vghtc.gov.tw
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objective: Normoalbuminuric chronic kidney disease (NA-CKD) is a distinct phenotype of diabetic kidney disease, but the role of diabetic retinopathy (DR) in predicting long-term mortality among these patients still yet to be elucidated. We aimed to investigate the effects of DR and chronic kidney disease (CKD) on mortality in type 2 diabetic patients with normoalbuminuria.

Design: We conducted this study as a retrospective cohort study.

Setting: We collected clinical information from the medical record in a public medical center in central Taiwan.

Participants: Type 2 diabetic patients (n = 665) hospitalized due to poor glucose control were consecutively enrolled and followed for a median of 6.7 years (interquartile range, 4.1–9.6 years). Patients with either urinary protein excretion >150 mg/day or urine albumin excretion >30 mg/day were excluded.

Primary outcome measure: All-cause mortality served as the follow-up outcome. Mortality data were obtained from the national registry in Taiwan.

Results: The patients with CKD and DR showed the highest mortality rate (log-rank P <0.001). The risks of all-cause mortality (HR: 2.422; 95% CI: 1.652, 3.552) and cardiovascular mortality (HR: 2.550; 95% CI: 1.469, 4.429) were significantly higher in patients with CKD and DR than those without CKD and DR after adjustment for age, gender

1
2
3
4 diabetes duration, body mass index, systolic blood pressure, total cholesterol, metformin
5
6 treatment, and insulin treatment.
7

8
9 **Conclusions:** DR is an independent predictor for all-cause and cardiovascular mortality in
10
11 type 2 diabetic inpatients with normoalbuminuria. In addition, there is a synergic effect of
12
13 DR with CKD on all-cause and cardiovascular mortality. Fundoscopy screening can
14
15 provide additive information on mortality for type 2 diabetes, even with absence of
16
17 albuminuria.
18
19
20
21
22
23
24
25

26 **Strengths and limitations of this study**

- 27
28
29
30 ■ Twenty-four hour urine collection during the hospitalization
- 31
32
33
34 ■ A median follow-up period of 6.7 years
- 35
36
37
38 ■ Mortality data obtained from a National Health Insurance registry with a nationwide
39
40 coverage rate of over 99% in Taiwan
- 41
42
43
44 ■ Not only normoalbuminuria but also normoproteinuria included for analyses due to
45
46 limited case numbers
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

Diabetes is associated with microvascular complications is the leading cause of end-stage renal disease (ESRD) and blindness.¹⁻⁵ Diabetic kidney disease (DKD) is a complex and heterogeneous disease, especially in patients with type 2 diabetes.⁶ Urinary albumin is an important biomarker for DKD,⁷ and is predictive of all-cause and cardiovascular mortality.^{8,9} Extensive resources and efforts have focused on albuminuria, and its prevalence has been significantly reduced; however, the estimated glomerular filtration rate (eGFR) has still increased.¹⁰

Normoalbuminuria was reported in 36% of type 2 diabetic patients with CKD in the Third National Health and Nutrition Examination Survey (NHANES) 1988–1994,¹¹ whereas it was reported in 126 (48.1 %) out of 262 diabetic patients with CKD in the NHANES 2005–2008.¹⁰ The prevalence of normoalbuminuria in CKD seems to have increased 15 years later.^{10,11} With the recent progress that has been made in the management of diabetic complications, it appears that the paradigm has shifted, with the phenotype of normoalbuminuric chronic kidney disease (NA–CKD) emerging.^{6,12} However, the mechanism by which NA–CKD leads to cardiovascular disease and mortality remains an area of research.

Diabetic retinopathy (DR) has been traditionally recognized as an early reflection of general microangiopathy in patients with type 2 diabetes.^{3,13,14} Accumulating evidence has shown that DR is a predictor of cardiovascular disease and all-cause mortality in subjects

1
2
3
4 with type 2 diabetes.¹⁵⁻¹⁸ However, some studies have reported that DR is not predictive of
5
6 mortality while the presence of DKD,^{19,20} and the association between DR and cardiovascular
7
8 disease becomes non-significant after adjusting for albuminuria.²¹⁻²³
9
10

11
12 We aimed to investigate the mortality risk among type 2 diabetic patients without
13
14 albuminuria, and we hypothesized that DR was predictive of long-term mortality in type 2
15
16 diabetic patients with NA-CKD.
17
18
19
20
21
22

23 **METHODS**

24 *Setting and participants*

25
26
27
28
29 This retrospective cohort study was conducted at Taichung Veterans General Hospital.
30
31
32 Clinical data were obtained by reviewing medical records of diabetic patients hospitalized
33
34 between August 1996 and August 2007. The inclusion criteria were (1) adult type 2 diabetic
35
36 inpatients in the Endocrinology and Metabolism section, (2) admission due to a primary
37
38 diagnosis of poor glucose control, and (3) performance of 24-hour urine collection for
39
40 albumin or protein during the hospitalization. The exclusion criteria included (1) urinary
41
42 protein excretion ≥ 150 mg/day or urine albumin excretion ≥ 30 mg/day,²⁴ (2) death during
43
44 this hospitalization, (3) systolic blood pressure < 90 mmHg, (4) urine volume < 300 ml/day,
45
46 and (5) the unavailability of a report documenting an eye fundal examination for retinopathy
47
48
49
50
51
52
53
54
55
56
57
58
59
60 by an ophthalmologist during the hospitalization. In repeatedly hospitalized patients, data

1
2
3
4 were only recorded from the last admission during the study period. The study complies with
5
6 the Declaration of Helsinki and the research protocol was approved by the Institutional
7
8
9 Review Board of Taichung Veterans General Hospital.
10

11 12 13 14 15 *Variables*

16
17 Normal urinary albumin was defined as a 24-hour urine albumin excretion < 30mg.²⁴⁻²⁶
18
19 In those inpatients with only protein detected, however, normal urine protein was defined as
20
21 24-hour urine protein < 150 mg.²⁴ CKD was defined as an estimated glomerular filtration
22
23 rate (eGFR) < 60 mL/min/1.73m². The eGFR was calculated by the Modification of Diet in
24
25 Renal Disease (MDRD) equation: $186 \times [\text{serum creatinine (mg/dL)}]^{-1.154} \times [\text{age (year)}]^{-0.203} (\times$
26
27 $0.742, \text{ if female) mL/min/1.73m}^2$.²⁵
28
29
30
31
32
33

34
35 Diabetic retinopathy (DR) included nonproliferative diabetic retinopathy (NPDR) and
36
37 proliferative diabetic retinopathy (PDR).²⁷ DR was screened using fundoscopic examinations
38
39 by ophthalmologists based on formal consultations. Retinal angiography (CF-60UVi fundus
40
41 camera, Canon, Japan) was subsequently arranged for confirmation of retinopathy diagnosis
42
43 if there were abnormal fundoscopic findings. Hypertension was defined as blood pressure
44
45 higher than 130/80 mmHg or a history of anti-hypertensive medications being prescribed.
46
47
48
49 Mortality data up to December 2011 were provided by the Collaboration Center of Health
50
51 Information Application, Department of Health, Executive Yuan, Taiwan.
52
53
54
55
56
57
58
59
60

Measurement

Biochemistry was assessed from blood samples collected after overnight fasting during hospitalization. HbA1c was determined using cation-exchange HPLC (NGSP certified; G8, TOSOH, Tokyo, Japan). Lipids were determined using enzymatic methods (Advia 1800, Siemens, New York, USA). Creatinine was determined using the Jaffé method (Advia 1800, Siemens, New York, USA). Urine protein was determined using the dye-binding assay, and urine albumin using the immune-turbidimetric method (Advia 1800, Siemens, New York, USA).

Statistical Analysis

Continuous data are presented as mean \pm standard deviation (SD). Categorical data are presented as number (n) with percentage (%). The linear correlation of daily excretion between urine protein and albumin was determined by Spearman's rank correlation coefficient. The receiver operating characteristic (ROC) analysis curve was applied to determine the optimal cut-off point of urine protein for normoalbuminuria. The one-way analysis of variance (ANOVA) was used to determine the significance of the differences among groups. Pairwise multiple comparisons were conducted to determine the significance of the differences between two groups if a statistically significant difference was found by the

1
2
3
4 one-way ANOVA. The Chi-square test was conducted to compare categorical variables across
5
6
7 groups. The overall significance of univariate survival analysis was detected by the log-rank
8
9
10 test using Kaplan–Meier analysis. Cox proportional hazards regression analyses were
11
12
13 conducted to determine the hazard ratios of risk factors. A value of $P < 0.05$ was considered
14
15
16 statistically significant. Statistical analysis was performed using SPSS 22.0 (IBM, Armonk,
17
18 NY, USA).

23 RESULTS

26 *Comparison of cutoff values for daily urinary protein and albumin excretion*

29 In 2482 diabetic inpatients who had undergone 24-hour urine collection, there were only
30
31
32 245 subjects who had the data for both urine albumin and protein in the same urine sample.
33
34
35 The median daily protein excretion was 184 mg (interquartile range, 80–620 mg); and the
36
37
38 median daily albumin excretion was 58 mg (interquartile range, 15–362 mg). There was a
39
40
41 significant positive correlation between daily urine protein and albumin excretion ($r = 0.884$,
42
43
44 $P < 0.001$). Using receiver operating characteristic (ROC) analysis to differentiate a normal
45
46
47 urine albumin excretion (<30 mg/day), the area under the curve in ROC analysis was 0.956
48
49
50 (95% confidence interval 0.932 to 0.979, $P < 0.001$; Fig. 1). The optimum diagnostic cutoff
51
52
53 value for daily urine protein was 145 mg, which corresponded to a sensitivity of 93.8% and
54
55
56 specificity of 86.5% for normoalbuminuria. Using 150 mg as diagnostic cutoff value of daily
57
58
59

1
2
3
4 urine protein again also gave a sensitivity of 93.8% and specificity of 86.5% for
5
6 normoalbuminuria.
7

8 9 10 11 12 *Comparison of the outcomes between subjects with and without fundal examination* 13

14
15 A total of 665 patients met the criteria for enrollment in the study and were included in
16
17 these analyses (Fig. 2). In comparison with the 238 patients who were eligible for all the
18
19 criteria except for lacking a fundal examination for retinopathy, there were no statically
20
21 significant differences in age (62 ± 14 vs. 63 ± 15 years, $P = 0.777$), gender (56.5% men vs.
22
23 61.3% men, $P = 0.226$), diabetes duration (8.7 ± 7.7 vs. 8.9 ± 8.6 years, $P = 0.789$), eGFR (73
24
25 ± 29 vs. 71 ± 30 mL/min/1.73m², $P = 0.642$), all-cause mortality incidence (6.6 vs. 6.5
26
27 events/100 person-years, log-rank test $P = 0.888$), and cardiovascular mortality (2.9 vs. 2.9
28
29 events/100 person-years, log-rank test $P = 0.965$).
30
31
32
33
34
35
36
37
38
39

40 *The risk of long-term mortality in CKD or DR in subjects with normoalbuminuria* 41

42
43 There were 229 (34.4%) subjects with CKD and 210 (31.6%) with DR in the 665
44
45 enrolled type 2 diabetic inpatients with normoalbuminuria. During a median follow-up of 6.7
46
47 years (interquartile range between 4.1–9.6years), the all-cause mortality rate was higher in
48
49 the subjects with CKD than in those without CKD (9.4 vs. 5.4 events/100 person-years,
50
51 log-rank test $P < 0.001$); and the rate was also higher in the subjects with DR than those
52
53
54
55
56
57
58
59
60

1
2
3
4 without DR (9.0 vs. 5.6 events/100 person-years, log-rank test $P < 0.001$). The cardiovascular
5
6 mortality rate was higher in subjects with CKD than in those without CKD (4.2 vs. 2.4
7
8 events/100 person-years, log-rank test $P < 0.001$); this rate was also higher in subjects with
9
10 DR than in those without DR (4.5 vs. 2.2 events/100 person-years, log-rank test $P < 0.001$).
11
12
13
14
15
16
17

18 *A synergistic effect of retinopathy and CKD on long-term mortality*

19
20 The proportion of subjects with DR was not significantly different between the subjects
21
22 with CKD and those without CKD (34.9% vs. 29.8%, $P = 0.207$). The 665 patients were
23
24 separated into four groups based on CKD and DR, including (1) patients without CKD or DR
25
26 in the CKD(-)DR(-) group, (2) patients with DR but not CKD in the CKD(-)DR(+) group, (3)
27
28 patients with CKD but not DR in the CKD(+)DR(-) group, and (4) patients with both CKD
29
30 and DR in the CKD(+)DR(+) group. Table 1 shows all the clinical characteristics of patients
31
32 among these four groups. Figure 3 shows that survival rates were significantly different cross
33
34 these four groups (log-rank test $P < 0.001$) by Kaplan–Meier analysis. The highest mortality
35
36 incidence (12.4 events/100 person-years) was observed in the CKD(+)DR(+) group, which
37
38 was significantly higher than the 8.1 events/100 person-years in the CKD(+)DR(-) group (P
39
40 = 0.010), the 7.4 events/100 person-years in the CKD(-)DR(+) group ($P = 0.004$), and the 4.6
41
42 events/100 person-years in the CKD(-)DR(-) group ($P < 0.001$). The incidences of mortality
43
44 in the CKD(+)DR(-) and CKD(-)DR(+) groups were also significantly higher than those in
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 the CKD(-)DR(-) group ($P < 0.001$ and $P = 0.003$, respectively). However, there was no
4
5
6 significant difference in the mortality incidence between the CKD(+)DR(-) and
7
8
9 CKD(-)DR(+) groups ($P = 0.479$).
10

11 12 13 14 15 *Cox regression analysis for all-cause and cardiovascular mortalities*

16
17 To identify the predictive factors for long-term mortality, univariate Cox regression
18
19 analysis was conducted for all the enrolled subjects. In addition to the different groups
20
21 categorized by CKD and DR, age, gender, diabetes duration, body mass index (BMI), systolic
22
23 blood pressure, total cholesterol, metformin treatment and insulin treatment were significantly
24
25 associated with total mortality. Using multivariate Cox regression analysis, patients with
26
27 CKD and DR have the highest hazard ratio (2.422, 95% CI: 1.652–3.552) for all-cause
28
29 mortality in comparison with the ones without CKD or DR after adjustment for age, gender,
30
31 diabetes duration, BMI, systolic blood pressure, total cholesterol, metformin treatment and
32
33 insulin treatment (Table 2A); the patients with CKD and DR also had the highest hazard ratio
34
35 (2.550, 95% CI: 1.469 – 4.429) for cardiovascular mortality in comparison to the ones
36
37 without CKD or DR after adjustment for age, gender, diabetes duration, BMI and systolic
38
39 blood pressure (Table 2B).
40
41
42
43
44
45
46
47
48
49
50
51
52
53

54 **DISCUSSION**

55
56
57
58
59
60

1
2
3
4 In this retrospective cohort study, we found that patients with NA–CKD have a higher
5
6 risk of all-cause mortality compared with patients without CKD. Furthermore, the presence of
7
8 DR imposed a higher mortality risk in patients with NA-CKD.
9
10

11
12 The mortality risk associated with NA-CKD has been debated. In the Casale Monferrato
13
14 study, which had an 11-year follow-up, eGFR showed a significantly inverse trend with
15
16 long-term mortality only in type 2 diabetic patients with macroalbuminuria, but not in those
17
18 with microalbuminuria or normoalbuminuria.²⁸ Conversely, several studies reported that low
19
20 eGFR was significantly associated with a higher all-cause mortality risk, independent of
21
22 albuminuria.²⁹⁻³³ The magnitude of the impact on all-cause mortality varied. Rigalleau et al.³⁴
23
24 reported that NA-CKD was associated with a very low risk of dialysis or mortality in
25
26 comparison with albuminuric CKD in diabetic patients during a 38-month follow-up study in
27
28 France. In an Asian study with a 44-month follow-up, albuminuria was associated with a
29
30 significantly higher risk of renal events, but not cardiovascular events in diabetic patients
31
32 with CKD.³⁵ In the present study, we found that NA-CKD is associated with an
33
34 approximately 1.8-fold increase in either all-cause mortality or cardiovascular disease,
35
36 compared with type 2 diabetic patients without CKD. In line with our findings, Hsieh et al.³⁶
37
38 reported that eGFR was inversely related to risk of cardiovascular events in type 2 diabetic
39
40 outpatients with normoalbuminuria during a 4-year follow-up study.
41
42
43
44
45
46
47
48
49
50
51
52

53
54 We postulated that heterogeneity in the pathogenesis of NA-CKD might contribute to
55
56
57
58
59
60

1
2
3
4 the differences in results. Different natural courses have been observed in the NA-CKD
5
6 phenotype: initial albuminuria with regression to normoalbuminuria with intensive
7
8 renin-angiotensin-aldosterone system (RAAS) inhibitor use in some diabetic patients, but
9
10 eGFR loss might be the only manifestation of renal involvement in others.^{12,37} Based on renal
11
12 biopsy, tubular-interstitial lesions and arterial hyalinosis were the predominant findings in
13
14 NA-CKD rather than the typical glomerulosclerotic lesions seen with albuminuria in diabetic
15
16 patients.^{38,39} With albuminuria regression due to the widespread use of RAAS inhibitors in
17
18 recent decades, NA-CKD is being found in majority of DKD patients. The number of patients
19
20 with normoalbuminuria has been found to be great than those with albuminuria in several
21
22 large studies of type 2 diabetic patients with CKD.⁴⁰⁻⁴² There is an urgent need to identify a
23
24 predictor of mortality among this distinct population.⁴³

25
26
27
28
29
30
31
32
33
34 Although there is a high prevalence of DR in type 2 diabetic patients with albuminuria,²⁰
35
36 the concordance between DR and CKD was lower in patients with normoalbuminuria than in
37
38 those with albuminuria.^{44,45} In the present study, we also found that the prevalence of
39
40 retinopathy was not significantly different between subjects with and without CKD. However,
41
42 our results showed a synergistic effect of CKD and DR on all-cause mortality and
43
44 cardiovascular mortality. Compared with the NEHANS III population, in which the
45
46 synergistic effect of CKD and retinopathy on mortality was also observed,⁴⁶ our findings
47
48 showed the evidence in type 2 diabetic inpatients even without albuminuria. Although similar
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 risk factors and cardiovascular effects for DR and CKD have been reported,^{30 47 48} the exact
4
5
6 mechanism for the superimposed DR effect on mortality in type 2 diabetic patients with
7
8
9 NA-CKD still needs further investigation.

10
11 In the present study, both isolated CKD, i.e. CKD(+)DR(-), and isolated DR, i.e.
12
13 CKD(-)DR(+), showed significantly higher mortality risks than those with neither CKD nor
14
15 DR in univariate analyses; however, the significant difference seemed to attenuate in isolated
16
17 CKD after adjustment for other traditional CV risk factors. NA-CKD has been reported to be
18
19 highly associated with cardiovascular risk factors.^{36 42} Therefore, the attenuation of the
20
21 mortality prediction after adjustment for cardiovascular risk factors might be more obvious in
22
23 isolated CKD in comparison with isolated DR. Furthermore, it is notable that a higher BMI
24
25 showed a protective effect for all-cause and cardiovascular mortality in the present study.
26
27
28 Although this seems somewhat contradictory to traditional concepts, we were not the only
29
30 one to report this paradoxical effect of BMI on mortality in subjects with diabetes.⁴⁹ Cea
31
32 Soriano et al.⁵⁰ reported that $BMI \geq 25 \text{ kg/m}^2$ predicted a lower mortality risk than $BMI < 25$
33
34 kg/m^2 in type 2 diabetic patients with CKD.

35
36 We acknowledge several limitations in our study. First, we enrolled subjects having not
37
38 only normoalbuminuria, but also normoproteinuria due to limited case numbers. Second, we
39
40 only included type 2 diabetic inpatients who were admitted to the hospital with the primary
41
42 diagnosis of poor glucose control. Third, we assessed the subjects only at baseline, but not in
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 follow-up. Therefore, treatment might have confounded the results after patients discharge.
5

6
7 In conclusion, DR is a significant predictor for all-cause and cardiovascular mortality in
8
9 type 2 diabetic inpatients with normoalbuminuria. Presence of DR also showed a synergistic
10
11 impact on mortality for type 2 diabetic inpatients with NA-CKD. Screening for DR and
12
13 eGFR may help identify those who harbor a high mortality risk after discharge in type 2
14
15 diabetic inpatients hospitalized due to poor glucose control, even with normoalbuminuria.
16
17
18
19
20
21
22

23 **Funding:** This work was supported by Taichung Veterans General Hospital, Taichung,
24
25 Taiwan (grant number TCVGH-1063501E, TCVGH-1063502C), and the Ministry of Science
26
27 and Technology, Taiwan (grant number MOST 105-2314-B-075A-003). The funders had no
28
29 role in the decision to submit the manuscript for publication.
30
31
32
33
34
35
36
37

38 **Acknowledgments:** Mortality data were provided by the Collaboration Center of Health
39
40 Information Application, Ministry of Health and Welfare, Executive Yuan. The statistical
41
42 analysis was performed by the Biostatistics Task Force of Taichung Veterans General
43
44 Hospital, Taichung, Taiwan.
45
46
47
48
49
50

51 **Competing interests:** The authors declare that they have no competing interests to declare.
52
53
54
55
56
57
58
59
60

1
2
3
4 **Data sharing statement:** No additional data are available.
5
6
7

8
9 **Author contributions**
10

11 YL, WHS and IL contributed to the study design. YL and IL participated in the data
12 collection. YL and IL participated in the analysis and interpretation of the data. YL drafted the
13 manuscript. IL had full access to the data in the study. IL is the guarantor. All the authors
14 performed a critical revision of the manuscript for important intellectual content.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

FIGURE LEGENDS

Figure 1. Receiver operating characteristic (ROC) analysis curves for differentiating normoalbuminuria based on daily urinary protein excretion.

Figure 2. Flow diagram of enrollment of study subjects with normoalbuminuria.

Figure 3. Kaplan-Meier curves showing survival rates grouped based on chronic kidney disease (CKD) and diabetic retinopathy (DR) in type 2 diabetic inpatients with normoalbuminuria.

References

1. Collins AJ, Foley RN, Chavers B, Gilbertson D, Herzog C, Johansen K, *et al.* 'United States Renal Data System 2011 Annual Data Report: Atlas of chronic kidney disease & end-stage renal disease in the United States. *Am J Kidney Dis* 2012;59:A7, e1-420.
2. Hwang SJ, Tsai JC, Chen HC. Epidemiology, impact and preventive care of chronic kidney disease in Taiwan. *Nephrology (Carlton)* 2010;15 Suppl 2:3-9.
3. Crawford TN, Alfaro DV, 3rd, Kerrison JB, Jablon EP. Diabetic retinopathy and angiogenesis. *Curr Diabetes Rev* 2009;5:8-13.
4. Maffi P, Secchi A. The Burden of Diabetes: Emerging Data. *Dev Ophthalmol* 2017;60:1-5.
5. Klein BE. Overview of epidemiologic studies of diabetic retinopathy. *Ophthalmic Epidemiol* 2007;14:179-183.
6. Porrini E, Ruggenenti P, Mogensen CE, Barlovic DP, Praga M, Cruzado JM, *et al.* Non-proteinuric pathways in loss of renal function in patients with type 2 diabetes. *Lancet Diabetes Endocrinol* 2015;3:382-391.
7. American Diabetes A. 10. Microvascular Complications and Foot Care. *Diabetes Care* 2017;40:S88-S98.
8. Lee IT, Sheu WH, Lin SY. The Impact of Creatinine Clearance Rate, Daily Urinary Albumin, and Their Joint Effect on Predicting Death in Diabetic Inpatients After Discharge: An Observational Study. *Medicine (Baltimore)* 2016;95:e2804.
9. Porrini E, Ruggenenti P, Mogensen CE, Barlovic DP, Praga M, Cruzado JM, *et al.* Non-proteinuric pathways in loss of renal function in patients with type 2 diabetes. *Lancet Diabetes Endocrinol* 2015;3:382-391.
10. Afkarian M, Zelnick LR, Hall YN, Heagerty PJ, Tuttle K, Weiss NS, *et al.* Clinical Manifestations of Kidney Disease Among US Adults With Diabetes, 1988-2014. *Jama* 2016;316:602-610.
11. Kramer HJ, Nguyen QD, Curhan G, Hsu CY. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. *Jama* 2003;289:3273-3277.
12. Pugliese G. Updating the natural history of diabetic nephropathy. *Acta Diabetol* 2014;51:905-915.
13. Willard AL, Herman IM. Vascular complications and diabetes: current therapies and future challenges. *J Ophthalmol* 2012;2012:209538.
14. Eshaq RS, Aldalati AMZ, Alexander JS, Harris NR. Diabetic retinopathy: Breaking the barrier. *Pathophysiology* 2017;24:229-241.
15. Cheung N, Wang JJ, Klein R, Couper DJ, Sharrett AR, Wong TY. Diabetic retinopathy and the risk of coronary heart disease: the Atherosclerosis Risk in Communities Study.

- 1
2
3 *Diabetes Care* 2007;30:1742-1746.
- 4 16. Xie J, Ikram MK, Cotch MF, Klein B, Varma R, Shaw JE, *et al.* Association of Diabetic
5 Macular Edema and Proliferative Diabetic Retinopathy With Cardiovascular Disease: A
6 Systematic Review and Meta-analysis. *JAMA Ophthalmol* 2017;135:586-593.
- 7 17. Alonso N, Traveset A, Rubinat E, Ortega E, Alcubierre N, Sanahuja J, *et al.* Type 2
8 diabetes-associated carotid plaque burden is increased in patients with retinopathy
9 compared to those without retinopathy. *Cardiovasc Diabetol* 2015;14:33.
- 10 18. Ellis TP, Choudhury RH, Kaul K, Chopra M, Kohner EM, Tarr JM, *et al.* Diabetic
11 retinopathy and atherosclerosis: is there a link? *Curr Diabetes Rev* 2013;9:146-160.
- 12 19. Kramer CK, Rodrigues TC, Canani LH, Gross JL, Azevedo MJ. Diabetic retinopathy
13 predicts all-cause mortality and cardiovascular events in both type 1 and 2 diabetes:
14 meta-analysis of observational studies. *Diabetes Care* 2011;34:1238-1244.
- 15 20. Hsieh YM, Lee WJ, Sheu WH, Li YH, Lin SY, Lee IT. Inpatient screening for
16 albuminuria and retinopathy to predict long-term mortality in type 2 diabetic patients: a
17 retrospective cohort study. *Diabetol Metab Syndr* 2017;9:29.
- 18 21. Torffvit O, Lovestam-Adrian M, Agardh E, Agardh CD. Nephropathy, but not retinopathy,
19 is associated with the development of heart disease in Type 1 diabetes: a 12-year
20 observation study of 462 patients. *Diabet Med* 2005;22:723-729.
- 21 22. van Hecke MV, Dekker JM, Stehouwer CD, Polak BC, Fuller JH, Sjolie AK, *et al.*
22 Diabetic retinopathy is associated with mortality and cardiovascular disease incidence:
23 the EURODIAB prospective complications study. *Diabetes Care* 2005;28:1383-1389.
- 24 23. Parving HH, Mogensen CE, Thomas MC, Brenner BM, Cooper ME. Poor prognosis in
25 proteinuric type 2 diabetic patients with retinopathy: insights from the RENAAL study.
26 *Qjm* 2005;98:119-126.
- 27 24. Webster AC, Nagler EV, Morton RL, Masson P. Chronic Kidney Disease. *Lancet*
28 2017;389:1238-1252.
- 29 25. Inker LA, Astor BC, Fox CH, Isakova T, Lash JP, Peralta CA, *et al.* KDOQI US
30 commentary on the 2012 KDIGO clinical practice guideline for the evaluation and
31 management of CKD. *Am J Kidney Dis* 2014;63:713-735.
- 32 26. American Diabetes Association. Standards of medical care in diabetes--2014. *Diabetes*
33 *Care* 2014;37 Suppl 1:S14-80.
- 34 27. Wilkinson CP, Ferris FL, 3rd, Klein RE, Lee PP, Agardh CD, Davis M, *et al.* Proposed
35 international clinical diabetic retinopathy and diabetic macular edema disease severity
36 scales. *Ophthalmology* 2003;110:1677-1682.
- 37 28. Bruno G, Merletti F, Bargerò G, Novelli G, Melis D, Soddu A, *et al.* Estimated
38 glomerular filtration rate, albuminuria and mortality in type 2 diabetes: the Casale
39 Monferrato study. *Diabetologia* 2007;50:941-948.
- 40 29. So WY, Kong AP, Ma RC, Ozaki R, Szeto CC, Chan NN, *et al.* Glomerular filtration rate,
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 cardiorenal end points, and all-cause mortality in type 2 diabetic patients. *Diabetes Care*
4 2006;29:2046-2052.
- 5
6 30. Wada T, Haneda M, Furuichi K, Babazono T, Yokoyama H, Iseki K, *et al.* Clinical
7 impact of albuminuria and glomerular filtration rate on renal and cardiovascular events,
8 and all-cause mortality in Japanese patients with type 2 diabetes. *Clin Exp Nephrol*
9 2014;18:613-620.
- 10
11 31. Palsson R, Patel UD. Cardiovascular complications of diabetic kidney disease. *Adv*
12 *Chronic Kidney Dis* 2014;21:273-280.
- 13
14 32. Toyama T, Furuichi K, Ninomiya T, Shimizu M, Hara A, Iwata Y, *et al.* The impacts of
15 albuminuria and low eGFR on the risk of cardiovascular death, all-cause mortality, and
16 renal events in diabetic patients: meta-analysis. *PLoS One* 2013;8:e71810.
- 17
18 33. Svensson MK, Cederholm J, Eliasson B, Zethelius B, Gudbjornsdottir S. Albuminuria
19 and renal function as predictors of cardiovascular events and mortality in a general
20 population of patients with type 2 diabetes: a nationwide observational study from the
21 Swedish National Diabetes Register. *Diab Vasc Dis Res* 2013;10:520-529.
- 22
23 34. Rigalleau V, Lasseur C, Raffaitin C, Beauvieux MC, Barthe N, Chauveau P, *et al.*
24 Normoalbuminuric renal-insufficient diabetic patients: a lower-risk group. *Diabetes Care*
25 2007;30:2034-2039.
- 26
27 35. Lee E, Oh HJ, Park JT, Han SH, Ryu DR, Kang SW, *et al.* The Incidence of
28 Cardiovascular Events Is Comparable Between Normoalbuminuric and Albuminuric
29 Diabetic Patients With Chronic Kidney Disease. *Medicine (Baltimore)* 2016;95:e3175.
- 30
31 36. Hsieh YT, Kuo JF, Su SL, Chen JF, Chen HC, Hsieh MC. Subnormal Estimated
32 Glomerular Filtration Rate Strongly Predict Incident Cardiovascular Events in Type 2
33 Diabetic Chinese Population With Normoalbuminuria. *Medicine (Baltimore)*
34 2016;95:e2200.
- 35
36 37. Katayama S, Moriya T, Tanaka S, Tanaka S, Yajima Y, Sone H, *et al.* Low transition rate
37 from normo- and low microalbuminuria to proteinuria in Japanese type 2 diabetic
38 individuals: the Japan Diabetes Complications Study (JDCS). *Diabetologia*
39 2011;54:1025-1031.
- 40
41 38. Ekinci EI, Jerums G, Skene A, Crammer P, Power D, Cheong KY, *et al.* Renal structure
42 in normoalbuminuric and albuminuric patients with type 2 diabetes and impaired renal
43 function. *Diabetes Care* 2013;36:3620-3626.
- 44
45 39. Shimizu M, Furuichi K, Yokoyama H, Toyama T, Iwata Y, Sakai N, *et al.* Kidney lesions
46 in diabetic patients with normoalbuminuric renal insufficiency. *Clin Exp Nephrol*
47 2014;18:305-312.
- 48
49 40. Thomas MC, Macisaac RJ, Jerums G, Weekes A, Moran J, Shaw JE, *et al.*
50 Nonalbuminuric renal impairment in type 2 diabetic patients and in the general
51 population (national evaluation of the frequency of renal impairment co-existing with
52
53
54
55
56
57
58
59
60

- 1
2
3 NIDDM [NEFRON] 11). *Diabetes Care* 2009;32:1497-1502.
- 4 41. Penno G, Solini A, Bonora E, Fondelli C, Orsi E, Zerbini G, *et al.* Clinical significance
5 of nonalbuminuric renal impairment in type 2 diabetes. *J Hypertens* 2011;29:1802-1809.
- 6 42. Yokoyama H, Sone H, Oishi M, Kawai K, Fukumoto Y, Kobayashi M, *et al.* Prevalence
7 of albuminuria and renal insufficiency and associated clinical factors in type 2 diabetes:
8 the Japan Diabetes Clinical Data Management study (JDDM15). *Nephrol Dial*
9 *Transplant* 2009;24:1212-1219.
- 10 43. Pugliese G, Solini A, Bonora E, Fondelli C, Orsi E, Nicolucci A, *et al.* Chronic kidney
11 disease in type 2 diabetes: lessons from the Renal Insufficiency And Cardiovascular
12 Events (RIACE) Italian Multicentre Study. *Nutr Metab Cardiovasc Dis*
13 2014;24:815-822.
- 14 44. Penno G, Solini A, Zoppini G, Orsi E, Zerbini G, Trevisan R, *et al.* Rate and
15 determinants of association between advanced retinopathy and chronic kidney disease in
16 patients with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events
17 (RIACE) Italian multicenter study. *Diabetes Care* 2012;35:2317-2323.
- 18 45. Rodriguez-Poncelas A, Mundet-Tuduri X, Miravet-Jimenez S, Casellas A, Barrot-De la
19 Puente JF, Franch-Nadal J, *et al.* Chronic Kidney Disease and Diabetic Retinopathy in
20 Patients with Type 2 Diabetes. *PLoS One* 2016;11:e0149448.
- 21 46. Ricardo AC, Grunwald JE, Parvathaneni S, Goodin S, Ching A, Lash JP. Retinopathy and
22 CKD as predictors of all-cause and cardiovascular mortality: National Health and
23 Nutrition Examination Survey (NHANES) 1988-1994. *Am J Kidney Dis*
24 2014;64:198-203.
- 25 47. Grunwald JE, Pistilli M, Ying GS, Maguire M, Daniel E, Whittock-Martin R, *et al.*
26 Retinopathy and the Risk of Cardiovascular Disease in Patients With Chronic Kidney
27 Disease (from the Chronic Renal Insufficiency Cohort Study). *Am J Cardiol*
28 2015;116:1527-1533.
- 29 48. Semeraro F, Cancarini A, dell'Omo R, Rezzola S, Romano MR, Costagliola C. Diabetic
30 Retinopathy: Vascular and Inflammatory Disease. *J Diabetes Res* 2015;2015:582060.
- 31 49. Chang HW, Li YH, Hsieh CH, Liu PY, Lin GM. Association of body mass index with
32 all-cause mortality in patients with diabetes: a systemic review and meta-analysis.
33 *Cardiovasc Diagn Ther* 2016;6:109-119.
- 34 50. Cea Soriano L, Johansson S, Stefansson B, Rodriguez LA. Cardiovascular events and
35 all-cause mortality in a cohort of 57,946 patients with type 2 diabetes: associations with
36 renal function and cardiovascular risk factors. *Cardiovasc Diabetol* 2015;14:38.
- 37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. The clinical data of patients according to the presence CKD and DR

	CKD(-)DR(-) (n = 306)	CKD(-)DR(+) (n = 130)	CKD(+DR(-) (n = 149)	CKD(+DR(+) (n = 80)	P-value
Age (years)	57 ± 15	62 ± 13	69 ± 10	70 ± 9	<0.001
Male, n (%)	189 (61.8%)	63 (48.5%)	82 (55.0%)	42 (52.5%)	0.057
BMI (kg/m ²)	23.7 ± 4.5	23.3 ± 4.0	24.2 ± 4.1	24.2 ± 4.3	0.367
Systolic blood pressure (mmHg)	124 ± 14	129 ± 15	127 ± 15	128 ± 14	0.004
Diastolic blood pressure (mmHg)	74 ± 11	75 ± 10	71 ± 9	72 ± 10	0.003
Diabetes duration (years)	6.7 ± 6.7	11.4 ± 7.4	7.9 ± 7.7	13.2 ± 8.4	<0.001
Current smoker, n (%)	96 (31.4%)	36 (27.7%)	31 (20.8%)	13 (16.3%)	0.014
White blood cell count (10 ⁶ /L)	7836 ± 5193	7210 ± 2421	8258 ± 3504	8358 ± 3285	0.227
HbA1c (%)	11.5 ± 2.9	10.6 ± 2.3	10.4 ± 3.3	9.3 ± 2.6	<0.001
Total cholesterol (mmol/L)	4.8 ± 1.3	5.0 ± 1.3	4.6 ± 1.3	4.7 ± 1.5	0.197
Triglyceride (mmol/L)	1.9 ± 1.9	1.9 ± 2.2	2.0 ± 2.2	1.8 ± 1.3	0.882
HDL cholesterol (mmol/L)	1.1 ± 0.4	1.1 ± 0.4	1.0 ± 0.3	1.0 ± 0.4	0.149
eGFR (mL/min/1.73m ²)	88 ± 23	87 ± 20	45 ± 13	42 ± 15	<0.001
Hypertension, n (%)	171 (55.9%)	93 (71.5%)	113 (75.8%)	63 (78.8%)	<0.001
Antihypertensive agents, n (%)	91 (29.7%)	63 (48.5%)	90 (60.4%)	47 (58.8%)	<0.001
Oral antihyperglycemic drugs, n (%)	151 (49.3%)	65 (50.0%)	53 (35.6%)	27 (33.8%)	0.005
Insulin secretagogues, n (%)	127 (41.5%)	56 (43.1%)	46 (30.9%)	23 (28.8%)	0.027
Metformin, n (%)	95 (31.0%)	41 (31.5%)	26 (17.4%)	17 (21.3%)	0.007
Thiazolidinediones, n (%)	6 (2.0%)	5 (3.8%)	2 (1.3%)	0 (0.0%)	0.230
α-glucosidase inhibitor, n (%)	10 (3.3%)	5 (3.8%)	3 (2.0%)	2 (2.5%)	0.811
Insulin therapy, n (%)	231 (75.5%)	80 (61.5%)	70 (47.0%)	38 (47.5%)	<0.001
Statins, n (%)	28 (9.2%)	12 (9.2%)	17 (11.4%)	12 (15.0%)	0.442

BMI= body mass index, CKD= chronic kidney disease, DR= diabetic retinopathy, HbA1c= glycated hemoglobin, HDL= high-density lipoprotein.

Table 2. Results of Cox regression analysis for the effects of risk factors on (A) all-cause and (B) cardiovascular mortality**(A) All-cause mortality**

	Univariate model			Multivariate model					
	Crude			Model 1			Model 2		
	HR	95%CI	P-value	HR	95%CI	P-value	HR	95%CI	P-value
CKD(-)DR(-)	1.000			1.000			1.000		
CKD(-)DR(+)	1.590	(1.179, 2.145)	0.002	1.556	(1.148, 2.108)	0.004	1.674	(1.181, 2.373)	0.004
CKD(+)DR(-)	1.842	(1.377, 2.463)	<0.001	1.416	(1.042, 1.924)	0.026	1.299	(0.910, 1.855)	0.149
CKD(+)DR(+)	2.791	(2.016, 3.866)	<0.001	2.209	(1.573, 3.101)	<0.001	2.422	(1.652, 3.552)	<0.001
Age (every 10 years)	1.455	(1.318, 1.607)	<0.001	1.328	(1.197, 1.472)	<0.001	1.313	(1.161, 1.485)	<0.001
Gender (male)	1.763	(1.394, 2.229)	<0.001	1.763	(1.388, 2.239)	<0.001	1.471	(1.111, 1.947)	0.007
Current smoker (yes/no)	1.223	(0.958, 1.561)	0.107						
Diabetes duration (every 1 year)	1.014	(1.000, 1.029)	0.046				1.005	(0.987, 1.024)	0.597
BMI (every 1 kg/m ²)	0.959	(0.931, 0.987)	0.004				0.957	(0.927, 0.989)	0.008
Systolic BP (every 10 mmHg)	1.081	(1.002, 1.167)	0.045				1.018	(0.929, 1.116)	0.697
HbA1c (every 1%)	0.969	(0.927, 1.013)	0.163						
Total cholesterol (every 1 mmol/L)	0.847	(0.769, 0.933)	<0.001				0.892	(0.801, 0.994)	0.039
Metformin (yes/no)	0.776	(0.604, 0.998)	0.049				0.806	(0.582, 1.117)	0.196
Insulin secretagogues (yes/no)	0.851	(0.677, 1.070)	0.167						
Insulin therapy (yes/no)	0.777	(0.619, 0.974)	0.029				0.959	(0.702, 1.310)	0.792
Statins (yes/no)	1.090	(0.763, 1.557)	0.635						

BMI= body mass index, BP= blood pressure, HbA1c= glycated hemoglobin, CI = confidence interval, HR = hazard ratio

(B) Cardiovascular mortality

	Univariate model			Multivariate model					
	Crude			Model 1			Model 2		
	HR	95%CI	P-value	HR	95%CI	P-value	HR	95%CI	P-value
CKD(-)DR(-)	1.000			1.000			1.000		
CKD(-)DR(+)	2.092	(1.340, 3.267)	0.001	2.039	(1.297, 3.203)	0.002	1.965	(1.201, 3.215)	0.007
CKD(+)DR(-)	1.937	(1.221, 3.072)	0.005	1.387	(0.855, 2.251)	0.185	1.393	(0.826, 2.349)	0.214
CKD(+)DR(+)	3.601	(2.215, 5.854)	<0.001	2.710	(1.634, 4.493)	<0.001	2.550	(1.469, 4.429)	<0.001
Age (every 10 years)	1.615	(1.377, 1.894)	<0.001	1.445	(1.224, 1.706)	<0.001	1.430	(1.184, 1.726)	<0.001
Gender (male)	2.124	(1.472, 3.066)	<0.001	2.132	(1.465, 3.102)	<0.001	2.089	(1.364, 3.200)	<0.001
Current smoker (yes/no)	1.326	(0.922, 1.908)	0.128						
Diabetes duration (every 1 year)	1.023	(1.002, 1.044)	0.029				1.004	(0.977, 1.032)	0.772
BMI (every 1 kg/m ²)	0.885	(0.843, 0.928)	<0.001				0.877	(0.836, 0.921)	<0.001
Systolic BP (every 10 mmHg)	1.157	(1.034, 1.295)	0.011				1.047	(0.927, 1.184)	0.459
HbA1c (every 1%)	0.977	(0.914, 1.045)	0.503						
Total cholesterol (every 1 mmol/L)	0.899	(0.780, 1.035)	0.138						
Metformin (yes/no)	0.819	(0.562, 1.193)	0.297						
Insulin secretagogues (yes/no)	0.950	(0.675, 1.339)	0.771						
Insulin therapy (yes/no)	0.900	(0.635, 1.276)	0.554						
Statins (yes/no)	0.788	(0.425, 1.460)	0.448						

BMI= body mass index, BP= blood pressure, HbA1c= glycated hemoglobin, CI = confidence interval, HR = hazard ratio

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60





Figure 1

196x133mm (300 x 300 DPI)



CKD = chronic kidney disease, CVD = cardiovascular disease, DR = diabetic retinopathy

1

Figure 2

210x297mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 3

164x129mm (300 x 300 DPI)

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cohort studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1,2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2,3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4,5
Objectives	3	State specific objectives, including any prespecified hypotheses	5
Methods			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	5
		(b) For matched studies, give matching criteria and number of exposed and unexposed	NA
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7
Bias	9	Describe any efforts to address potential sources of bias	14,15
Study size	10	Explain how the study size was arrived at	8
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	7,8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	7,8
		(b) Describe any methods used to examine subgroups and interactions	10
		(c) Explain how missing data were addressed	NA
		(d) If applicable, explain how loss to follow-up was addressed	NA
		(e) Describe any sensitivity analyses	8,9
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	9, Figure 2
		(b) Give reasons for non-participation at each stage	Figure 2
		(c) Consider use of a flow diagram	Figure 2
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Table 1
		(b) Indicate number of participants with missing data for each variable of interest	NA
		(c) Summarise follow-up time (eg, average and total amount)	9
Outcome data	15*	Report numbers of outcome events or summary measures over time	9,10, Figure 2
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Table 2
		(b) Report category boundaries when continuous variables were categorized	11
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	NA
Discussion			
Key results	18	Summarise key results with reference to study objectives	12
Limitations			
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	12-14
Generalisability	21	Discuss the generalisability (external validity) of the study results	12-14
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	14

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

A Synergistic Effect of Retinopathy and Chronic Kidney Disease on Long-term Mortality in Type 2 Diabetic Inpatients with Normal Urinary Albumin or Protein: A Retrospective Cohort Study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-021655.R1
Article Type:	Research
Date Submitted by the Author:	13-Mar-2018
Complete List of Authors:	Li, Yu-Hsuan; Taichung Veterans General Hospital, Division of Endocrinology and Metabolism, Department of Internal Medicine; Sheu, Wayne; Taichung Veterans General Hospital, Superintendent Lee, I-Te; Taichung Veterans General Hospital, Division of Endocrinology and Metabolism, Department of Internal Medicine
Primary Subject Heading:	Diabetes and endocrinology
Secondary Subject Heading:	Diabetes and endocrinology
Keywords:	Diabetic nephropathy & vascular disease < DIABETES & ENDOCRINOLOGY, Diabetic retinopathy < DIABETES & ENDOCRINOLOGY, Diabetes & endocrinology < INTERNAL MEDICINE

SCHOLARONE™
Manuscripts

Only

1
2
3 **A Synergistic Effect of Retinopathy and Chronic Kidney Disease on Long-term**
4 **Mortality in Type 2 Diabetic Inpatients with Normal Urinary Albumin or Protein: A**
5 **Retrospective Cohort Study**
6
7
8
9

10
11 Yu-Hsuan Li ¹, Wayne H-H Sheu ^{1,2}, I-Te Lee ^{1,2,3,*}
12
13

14
15
16 ¹Division of Endocrinology and Metabolism, Department of Internal Medicine, Taichung
17 Veterans General Hospital, Taichung, Taiwan
18

19
20 ² School of Medicine, National Yang-Ming University, Taipei, Taiwan
21

22 ³ School of Medicine, Chung Shan Medical University, Taichung, Taiwan
23
24
25
26

27 **Running title:** DR and CKD in DM with Normoalbuminuria
28
29
30
31

32 ***Correspondence:** I-Te Lee, MD, PhD,
33
34

35 No. 1650 Taiwan Boulevard, Sect. 4, Taichung 40705, Taiwan.
36
37

38 Tel: +886-4-23741300, Fax: +886-4-23741318, E-mail: itlee@vghtc.gov.tw
39
40
41
42

43 ***Correspondence and reprint to:** I-Te Lee MD, PhD. No. 1650 Taiwan Boulevard, Sect. 4,
44 Taichung 40705, Taiwan.
45
46

47 E-mail: itlee@vghtc.gov.tw
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objective: Normoalbuminuric chronic kidney disease (NA-CKD) is recognized as a distinct phenotype of diabetic kidney disease, but the role of diabetic retinopathy (DR) in predicting long-term mortality among these patients remains unclear. Here, we aimed to investigate the effects of DR and chronic kidney disease (CKD) on mortality in type 2 diabetic patients with normoalbuminuria.

Design: We conducted this study as a retrospective cohort study.

Setting: We collected clinical information from the medical records of a public medical center in central Taiwan.

Participants: Patients with type 2 diabetes ($n = 665$) who were hospitalized due to poor glucose control were consecutively enrolled and followed for a median of 6.7 years (interquartile range, 4.1–9.6 years). Patients with either urinary protein excretion >150 mg/day or urine albumin excretion >30 mg/day were excluded.

Primary outcome measure: All-cause mortality served as the primary follow-up outcome, and the mortality data were obtained from the national registry in Taiwan.

Results: The patients with CKD and DR showed the highest mortality rate (log-rank $P < 0.001$). The risks of all-cause mortality (hazard ratio [HR], 2.263; 95% confidence interval [CI], 1.551–3.302) and cardiovascular mortality (HR, 2.471; 95% CI, 1.421–4.297) were significantly greater in patients with CKD and DR than in those without CKD or DR, after

1
2
3
4 adjusting for the associated risk factors.
5

6 **Conclusions:** DR is an independent predictor for all-cause and cardiovascular mortality in
7
8
9 type 2 diabetic inpatients with normoalbuminuria. Moreover, DR with CKD exerts a
10
11
12 synergistic effect on all-cause and cardiovascular mortality. Fundoscopy screening can
13
14
15 provide additive information on mortality in patients with type 2 diabetes, even among
16
17
18 those with NA-CKD.
19
20
21
22

23 **Strengths and limitations of this study**

- 24
25
26
27 ■ Twenty-four hour urine collection during the hospitalization period
28
29
30
- 31 ■ A median follow-up period of 6.7 years
32
33
34
- 35 ■ Mortality data obtained from a National Health Insurance registry with a nationwide
36
37 coverage rate of over 99% in Taiwan
38
39
40
- 41 ■ In addition to normoalbuminuria, normoproteinuria was also included in the analyses
42
43
44 due to limited case numbers
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

Diabetes is associated with microvascular complications, and is the leading cause of both end-stage renal disease (ESRD) and blindness.¹⁻⁵ Diabetic kidney disease (DKD) is a complex and heterogeneous disease, particularly among patients with type 2 diabetes.⁶ The urinary albumin level is an important biomarker for DKD,⁷ and is predictive of all-cause and cardiovascular mortality.^{8,9} Extensive resources and efforts have focused on understanding and preventing albuminuria, and its prevalence has consequently been significantly reduced; however, the prevalence of low estimated glomerular filtration rate (eGFR) has still increased among patients with diabetes.¹⁰

Normoalbuminuria was reported in 36% of type 2 diabetic patients with CKD in the Third National Health and Nutrition Examination Survey (NHANES) 1988–1994,¹¹ and was reported in 48.1 % of diabetic patients with CKD in the NHANES 2005–2008.¹⁰ The prevalence of normoalbuminuria in CKD appears to have increased over the 15 years.^{10,11} With the recent progress in the management of diabetic complications, it appears that this paradigm has shifted, and the phenotype of normoalbuminuric chronic kidney disease (NA-CKD) has emerged.^{6,12} Hence, the mechanism by which NA-CKD leads to cardiovascular disease and mortality remains a popular area of research.

Diabetic retinopathy (DR) has been traditionally recognized as an early reflection of general microangiopathy in patients with type 2 diabetes.^{3,13,14} Accumulating evidence has

1
2
3
4 shown that DR is a predictor of cardiovascular disease and all-cause mortality in subjects
5
6 with type 2 diabetes.¹⁵⁻¹⁸ However, some studies have reported that DR is not predictive of
7
8 mortality in the presence of DKD,^{19 20} and the association between DR and cardiovascular
9
10 disease becomes non-significant after adjusting for the albuminuria.²¹⁻²³
11
12
13
14

15 In the present study, we aimed to investigate the mortality risk among type 2 diabetic
16
17 patients without albuminuria, and we hypothesized that DR was predictive of long-term
18
19 mortality in type 2 diabetic patients with NA-CKD or without NA-CKD.
20
21
22
23
24
25

26 **METHODS**

27 *Setting and participants*

28
29
30
31 This retrospective cohort study was conducted at Taichung Veterans General Hospital.
32
33
34 Clinical data were obtained by reviewing the medical records of diabetic patients hospitalized
35
36 between August 1996 and August 2007. The inclusion criteria were (1) adult diabetic
37
38 inpatients based on the clinical diagnosis, (2) admission to the Endocrinology and
39
40 Metabolism section due to a primary diagnosis of poor glucose control, (3) availability of
41
42 eGFR data, and (4) performance of 24-hour urine collection for the determination of albumin
43
44 or protein levels during the hospitalization period. The exclusion criteria included (1) urinary
45
46 protein excretion ≥ 150 mg/day or urine albumin excretion ≥ 30 mg/day,²⁴ (2) death during
47
48 this hospitalization period, (3) systolic blood pressure < 90 mmHg, (4) urine volume < 300
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 ml/day, (5) diagnosis of diabetes other than type 2, and (6) the unavailability of reports
4
5
6 documenting eye fundal examinations for retinopathy by an ophthalmologist during the
7
8
9 hospitalization period. In repeatedly hospitalized patients, data recorded from the last
10
11
12 admission during the study period were used. The research protocol was approved by the
13
14
15 Institutional Review Board of Taichung Veterans General Hospital.

16 17 18 19 20 *Patient and Public Involvement*

21
22
23 All-cause mortality served as the primary outcome in this retrospective cohort study, and
24
25
26 the mortality data were obtained from the national registry in Taiwan. We collected clinical
27
28
29 information from the medical records at Taichung Veterans General Hospital. The
30
31
32 Institutional Review Board waived the need for informed consent before reviewing the
33
34
35 medical records.

36 37 38 39 40 *Variables*

41
42
43 A normal urinary albumin level was defined as 24-hour urine albumin excretion <
44
45
46 30mg.²⁴⁻²⁶ In those inpatients with only protein detected, however, normal urine protein was
47
48
49 defined as 24-hour urine protein < 150 mg.²⁴ CKD was defined as an eGFR < 60
50
51
52 mL/min/1.73m². The eGFR was calculated by the Modification of Diet in Renal Disease
53
54
55 (MDRD) equation: $186 \times [\text{serum creatinine (mg/dL)}]^{-1.154} \times [\text{age (year)}]^{-0.203} (\times 0.742, \text{ if}$

1
2
3
4 female) mL/min/1.73m².²⁵
5

6 DR includes nonproliferative diabetic retinopathy (NPDR) and proliferative diabetic
7 retinopathy (PDR).²⁷ DR was screened using fundoscopic examinations by ophthalmologists
8 based on formal consultations. Retinal angiography (CF-60UVi fundus camera, Canon, Japan)
9 was subsequently arranged for the confirmation of retinopathy diagnosis in cases with
10 abnormal fundoscopic findings. Hypertension was defined as blood pressure higher than
11 130/80 mmHg or a history of anti-hypertensive medications use. After medical information
12 was collected from our hospital, we also obtained the mortality data up to December 2011
13 from the Collaboration Center of Health Information Application, Department of Health,
14 Executive Yuan, Taiwan. The causes of death were categorized according to the International
15 Classification of Disease (ICD), 9th Revision, Clinical Modification diagnostic criteria before
16 2008 and according to the ICD-10 after 01 January, 2008.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42

43 *Measurement*

44 Biochemistry was assessed from blood samples collected after overnight fasting during
45 the hospitalization period. HbA1c levels were determined using cation-exchange HPLC
46 (NGSP certified; G8, TOSOH, Tokyo, Japan). Lipid levels were determined using
47 enzymatic methods (Advia 1800, Siemens, New York, USA). Creatinine levels were
48 determined using the Jaffé method (Advia 1800, Siemens, New York, USA). Urine protein
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 levels were determined using the dye-binding assay, and urine albumin levels were assessed
4
5
6 using the immune-turbidimetric method (Advia 1800, Siemens, New York, USA).
7
8
9

10 11 12 *Comparison of cutoff values of daily urinary protein excretion for normoalbuminuria* 13

14
15 Among the 2482 diabetic inpatients who had undergone 24-hour urine collection, only
16
17 245 had the data for both urine albumin and protein levels in the same urine sample. The
18
19 median level of daily protein excretion was 184 mg (interquartile range, 80–620 mg) and the
20
21 median level of daily albumin excretion was 58 mg (interquartile range, 15–362 mg). There
22
23 was a significant positive correlation between daily urine protein and albumin excretion ($r =$
24
25 0.884, $P < 0.001$). Receiver operating characteristic (ROC) curves were used to differentiate
26
27 normal urine albumin excretion (<30 mg/day), and we found that the area under the curve
28
29 was 0.956 (95% confidence interval [CI], 0.932–0.979; $P < 0.001$; supplementary figure).
30
31
32 The optimal diagnostic cutoff value for the daily urine protein level was 145 mg, which
33
34 corresponded to a sensitivity of 93.8% and specificity of 86.5% for normoalbuminuria. Using
35
36 150 mg as diagnostic cutoff value of daily urine protein also gave a sensitivity of 93.8% and
37
38 specificity of 86.5% for normoalbuminuria.
39
40
41
42
43
44
45
46
47
48
49
50
51

52 *Statistical analysis* 53

54 Continuous data are presented as mean \pm standard deviation (SD), whereas categorical
55
56
57
58
59
60

1
2
3
4 data are presented as number (n) with percentage (%). The linear correlation of daily
5
6 excretion between urine protein and albumin was determined using Spearman's rank
7
8
9 correlation coefficient. The ROC curve was used to determine the optimal cut-off value of
10
11
12 daily urine protein for normoalbuminuria. One-way analysis of variance (ANOVA) was used
13
14
15 to determine the significance of the differences among groups. Pairwise multiple comparisons
16
17
18 were conducted to determine the significance of the differences between two groups, if a
19
20
21 statistically significant difference was detected via one-way ANOVA; however,
22
23
24 Kruskal-Wallis tests were conducted to determine the significance of the differences in the
25
26
27 duration of diabetes, triglycerides levels and eGFR values among groups due to the presence
28
29
30 of a skewed distribution in these variables. The Chi-square test was used to compare
31
32
33 categorical variables across groups. The overall significance of univariate survival analysis
34
35
36 was determined by the log-rank test using Kaplan-Meier analysis. Cox proportional hazards
37
38
39 regression analyses were conducted to determine the hazard ratios of risk factors. The risk
40
41
42 factors in the univariate model were selected based on the findings in Table 1, whereas the
43
44
45 risk factors in model 2 were selected based on the statistical significance indicated in the
46
47
48 univariate model. Except the inclusion and exclusion criteria, the mean imputation method
49
50
51 was used for missing data. A value of $P < 0.05$ was considered statistically significant.
52
53
54
55
56
57
58
59
60 Statistical analysis was performed using SPSS 22.0 (IBM, Armonk, NY, USA).

RESULTS

Comparison of the outcomes between patients with and without fundal examination

A total of 665 patients with a median diabetes duration of 7 years (interquartile range, 2–12 years) met the criteria for enrollment in the study and were included in these analyses (figure 1). In comparison with the 238 patients who were eligible for all the criteria except for lacking a fundal examination for retinopathy, there were no statically significant differences in age (62 ± 14 vs. 63 ± 15 years, $P = 0.777$), gender (56.5% men vs. 61.3% men, $P = 0.226$), diabetes duration (8.7 ± 7.7 vs. 8.9 ± 8.6 years, $P = 0.789$), eGFR (73 ± 29 vs. 71 ± 30 mL/min/1.73m², $P = 0.642$), all-cause mortality incidence (6.6 vs. 6.5 events/100 person-years, log-rank test $P = 0.888$), and cardiovascular mortality (2.9 vs. 2.9 events/100 person-years, log-rank test $P = 0.965$).

Risk of long-term mortality in CKD or DR in patients with normoalbuminuria

There were 229 (34.4%) patients with CKD and 210 (31.6%) with DR in the 665 enrolled type 2 diabetic inpatients with normoalbuminuria. During a median follow-up of 6.7 years (interquartile range, 4.1–9.6years), 315 (47.4%) patients died from any cause; in particular, 138 patients died of cardiovascular disease (figure 1). The all-cause mortality rate was higher in the patients with CKD than in those without CKD (9.4 vs. 5.4 events/100 person-years, log-rank test $P < 0.001$); and the all-cause mortality rate was also higher in the

1
2
3 patients with DR than those without DR (9.0 vs. 5.6 events/100 person-years, log-rank test P
4
5
6 < 0.001). Moreover, the cardiovascular mortality rate was higher in patients with CKD than
7
8
9 in those without CKD (4.2 vs. 2.4 events/100 person-years, log-rank test P < 0.001); this rate
10
11
12 was also higher in patients with DR than in those without DR (4.5 vs. 2.2 events/100
13
14
15 person-years, log-rank test P < 0.001).
16
17
18
19

20 21 *A synergistic effect of retinopathy and CKD on long-term mortality*

22
23 The proportion of patients with DR was not significantly different between the patients
24
25 with CKD and those without CKD (34.9% vs. 29.8%, P = 0.207). The 665 patients were
26
27 separated into four groups based on the presence of CKD and DR, including (1) patients
28
29 without CKD or DR in the CKD(-)DR(-) group, (2) patients with DR but not CKD in the
30
31 CKD(-)DR(+) group, (3) patients with CKD but not DR in the CKD(+)DR(-) group, and (4)
32
33 patients with both CKD and DR in the CKD(+)DR(+) group. Table 1 shows all the clinical
34
35 characteristics of patients among these four groups. Figure 2 shows that survival rates were
36
37 significantly different across these four groups (log-rank test P < 0.001), as demonstrated by
38
39 Kaplan–Meier analysis. The highest mortality incidence (12.4 events/100 person-years) was
40
41 observed in the CKD(+)DR(+) group; this value was significantly higher than the 8.1
42
43 events/100 person-years in the CKD(+)DR(-) group (P = 0.010), the 7.4 events/100
44
45 person-years in the CKD(-)DR(+) group (P = 0.004), and the 4.6 events/100 person-years in
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 the CKD(-)DR(-) group ($P < 0.001$). The incidences of mortality in the CKD(+)DR(-) and
4
5
6 CKD(-)DR(+) groups were also significantly higher than that in the CKD(-)DR(-) group (P
7
8
9 < 0.001 and $P = 0.003$, respectively). However, there was no significant difference in the
10
11
12 mortality incidence between the CKD(+)DR(-) and CKD(-)DR(+) groups ($P = 0.479$).
13
14
15

16 17 *Cox regression analysis for all-cause and cardiovascular mortality*

18
19 To identify the predictive factors for long-term mortality, univariate Cox regression
20
21 analysis was conducted for all the enrolled patients. In addition to the different groups
22
23 categorized based on CKD and DR, age, gender, diabetes duration, body mass index (BMI),
24
25
26 systolic blood pressure, metformin treatment, insulin treatment, and diuretic treatment were
27
28
29 significantly associated with total mortality. Using multivariate Cox regression analysis,
30
31
32 patients with CKD and DR have the highest hazard ratio (2.263; 95% CI, 1.551–3.302) for
33
34
35 all-cause mortality in comparison with the ones without CKD or DR after adjustment for age,
36
37
38 gender, diabetes duration, BMI, systolic blood pressure, metformin treatment, insulin
39
40
41 treatment and diuretics treatment (Table 2A). Moreover, patients with CKD and DR also had
42
43
44 the highest hazard ratio (2.471; 95% CI, 1.421–4.297) for cardiovascular mortality in
45
46
47 comparison to the ones without CKD or DR after adjustment for age, gender, diabetes
48
49
50 duration, BMI, systolic blood pressure and angiotensin-converting enzyme (ACE) inhibitor or
51
52
53 angiotensin II receptor antagonist (ARB) treatment (Table 2B).
54
55
56
57
58
59
60

DISCUSSION

In this retrospective cohort study, we found that patients with NA-CKD have a higher risk of all-cause mortality compared with patients without CKD. Furthermore, the presence of DR imposed a higher mortality risk in patients with NA-CKD.

The mortality risk associated with NA-CKD remains controversial. In the Casale Monferrato study, which had an 11-year follow-up, eGFR showed a significantly inverse trend with long-term mortality only in type 2 diabetic patients with macroalbuminuria, but not in those with microalbuminuria or normoalbuminuria.²⁸ Conversely, several studies reported that low eGFR was significantly associated with a higher all-cause mortality risk, independent of albuminuria.²⁹⁻³³ The magnitude of the impact on all-cause mortality varied. Rigalleau et al.³⁴ reported that NA-CKD was associated with a very low risk of dialysis or mortality in comparison with albuminuric CKD in diabetic patients during a 38-month follow-up study in France. In an Asian study with a 44-month follow-up, albuminuria was associated with a significantly higher risk of renal events, but not cardiovascular events in diabetic patients with CKD.³⁵ In the present study, we found that NA-CKD is associated with an approximately 1.8-fold increase in either all-cause mortality or cardiovascular disease, compared with type 2 diabetic patients without CKD. In line with our findings, Hsieh et al.³⁶ reported that eGFR was inversely related to risk of cardiovascular events in type 2 diabetic

1
2
3
4 outpatients with normoalbuminuria during a 4-year follow-up study.
5

6 We postulated that heterogeneity in the pathogenesis of NA-CKD might contribute to
7
8 the differences in results. Different natural courses have been observed in the NA-CKD
9
10 phenotype: initial albuminuria with regression to normoalbuminuria with intensive
11
12 renin-angiotensin-aldosterone system (RAAS) inhibitor use in some diabetic patients, but
13
14 eGFR loss might be the only manifestation of renal involvement in others.^{12 37} Based on renal
15
16 biopsy, tubular-interstitial lesions and arterial hyalinosis were the predominant findings in
17
18 NA-CKD rather than the typical glomerulosclerotic lesions seen with albuminuria in diabetic
19
20 patients.^{38 39} With albuminuria regression due to the widespread use of RAAS inhibitors in
21
22 recent decades, NA-CKD is being found in majority of DKD patients. The number of patients
23
24 with normoalbuminuria has been found to be great than those with albuminuria in several
25
26 large studies of type 2 diabetic patients with CKD.⁴⁰⁻⁴² Hence, there is an urgent need to
27
28 identify the predictors of mortality among this distinct population.⁴³
29
30
31
32
33
34
35
36
37
38
39

40 In the present study, patients using ACE inhibitors or ARBs showed a higher risk of
41
42 cardiovascular mortality in the univariate model, and this finding may result from the higher
43
44 proportion of CKD patients using these drugs at baseline. In the multivariate model, the use
45
46 of ACE inhibitors or ARBs at baseline was not significantly associated with cardiovascular
47
48 mortality. Consistent with these findings, early ARB treatment was not found to significantly
49
50 improve eGFR in type 2 diabetic patients with urine albumin-to-creatinine ratio <300 mg/g.⁴⁴
51
52
53
54
55
56
57
58
59
60

1
2
3
4 Although there is a high prevalence of DR in type 2 diabetic patients with albuminuria,²⁰
5
6 the concordance between DR and CKD was lower in patients with normoalbuminuria than in
7
8 those with albuminuria.^{45 46} In the present study, we found that the prevalence of retinopathy
9
10 was not significantly different between patients with and without CKD. However, our results
11
12 showed a synergistic effect of CKD and DR on all-cause mortality and cardiovascular
13
14 mortality. Compared with the NEHANS III population, in which the synergistic effect of
15
16 CKD and retinopathy on mortality was also observed,⁴⁷ our findings showed the evidence in
17
18 type 2 diabetic inpatients even without albuminuria. Although similar risk factors and
19
20 cardiovascular effects for DR and CKD have been reported,^{30 48 49} the exact mechanism
21
22 underlying the superimposed DR effect on mortality in type 2 diabetic patients with
23
24 NA-CKD requires further investigation.
25
26
27
28
29
30
31
32
33

34
35 In the present study, both isolated CKD, i.e. CKD(+)DR(-), and isolated DR, i.e.
36
37 CKD(-)DR(+), showed significantly higher mortality risks than those with neither CKD nor
38
39 DR in univariate analyses; however, the significant difference seemed to attenuate in isolated
40
41 CKD after adjustment for other traditional cardiovascular risk factors. NA-CKD has been
42
43 reported to be highly associated with cardiovascular risk factors.^{36 42} Therefore, the
44
45 attenuation of the mortality prediction after adjustment for cardiovascular risk factors might
46
47 be more obvious in isolated CKD in comparison with isolated DR. Furthermore, it is notable
48
49 that a higher BMI showed a protective effect for all-cause and cardiovascular mortality in the
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 present study. Although this seems somewhat contradictory to traditional concepts, we were
5
6 not the only one to report this paradoxical effect of BMI on mortality in patients with
7
8 diabetes.⁵⁰ Cea Soriano et al.⁵¹ reported that $\text{BMI} \geq 25 \text{ kg/m}^2$ predicted a lower mortality risk
9
10 than $\text{BMI} < 25 \text{ kg/m}^2$ in type 2 diabetic patients with CKD.
11
12
13

14
15 Among type 2 diabetic patients with normoalbuminuria, high urine albumin excretion
16
17 (10–29 mg/day) was reportedly associated with multiple cardiovascular risk factors, as
18
19 compared to low urine albumin excretion ($< 10 \text{ mg/day}$).⁵² Recently, the highest tertile of the
20
21 urine albumin excretion rate was found to be associated with diabetic retinopathy and arterial
22
23 stiffness, in comparison to the lowest tertile among type 2 diabetic patients with
24
25 normoalbuminuria.^{53 54} In the present study, 257 patients without CKD had available urine
26
27 albumin data, including 108 patients with low normoalbuminuria ($< 10 \text{ mg/day}$) and 149
28
29 patients with high normoalbuminuria (10–29 mg/day). However, there was no significant
30
31 difference in DR prevalence ($P > 0.05$) or all-cause and cardiovascular mortality (both
32
33 log-rank test $P > 0.05$). Further investigations with a large number of cases will be needed to
34
35 evaluate the association between high normoalbuminuria and mortality.
36
37
38
39
40
41
42
43
44
45

46 We acknowledge several limitations in our study. First, we enrolled patients with not
47
48 only normoalbuminuria, but also normoproteinuria, due to the limited numbers of cases
49
50 overall. Second, we used the 24-hour urine data instead of spot-urine data, since the latter has
51
52 been well reported in type 2 outpatients previously.⁵⁵ Third, we only included type 2 diabetic
53
54
55
56
57
58
59
60

1
2
3
4 inpatients who were admitted to the hospital with a primary diagnosis of poor glucose control.

5
6 Fourth, we calculated eGFR using the MDRD equation instead of the CKD Epidemiology
7
8
9 Collaboration (EPI) equation as consensus had not been reached regarding the use of the
10
11
12 CKD-EPI equation in the Taiwanese population.⁵⁶ Finally, we assessed the patients only at
13
14
15 baseline, but not during the follow-up. Therefore, treatment might have confounded the
16
17
18 results following patients discharged.

19
20
21 In conclusion, DR is a significant predictor for all-cause and cardiovascular mortality in
22
23
24 type 2 diabetic inpatients with normoalbuminuria. Presence of DR also showed a synergistic
25
26
27 impact on mortality for type 2 diabetic inpatients with NA-CKD. Screening for DR and
28
29
30 eGFR may help identify those who harbor a high mortality risk after discharge in type 2
31
32
33 diabetic inpatients hospitalized due to poor glucose control, even with normoalbuminuria.

34
35
36
37 **Funding:** This work was supported by Taichung Veterans General Hospital, Taichung,
38
39
40 Taiwan (grant number TCVGH-TCVGH-1063501E, TCVGH-1063502C), and the Ministry
41
42
43 of Science and Technology, Taiwan (grant number MOST 105-2314-B-075A-003). The
44
45
46 funders had no role in the decision to submit the manuscript for publication.

47
48
49
50
51 **Acknowledgments:** Mortality data were provided by the Collaboration Center of Health
52
53
54 Information Application, Ministry of Health and Welfare, Executive Yuan. The statistical
55
56
57

1
2
3
4 analysis was performed by the Biostatistics Task Force of Taichung Veterans General
5
6 Hospital, Taichung, Taiwan.
7
8
9
10

11
12 **Competing interests:** The authors declare that they have no competing interests to declare.
13
14

15
16
17 **Data sharing statement:** No additional data are available.
18
19

20 21 22 23 **Author contributions**

24
25
26 YL, WHS and IL contributed to the study design. YL and IL participated in the data
27
28 collection. YL and IL participated in the analysis and interpretation of the data. YL drafted the
29
30 manuscript. IL had full access to the study data. IL is the guarantor. All the authors performed
31
32 a critical revision of the manuscript for important intellectual content.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 **FIGURE LEGENDS**
5

6 **Figure 1.** Flow diagram of enrollment of study subjects with normoalbuminuria.
7

8
9 **Figure 2.** Kaplan-Meier curves showing survival rates categorized according to chronic
10 kidney disease (CKD) and diabetic retinopathy (DR) in type 2 diabetic inpatients with
11
12
13
14
15 normoalbuminuria.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Collins AJ, Foley RN, Chavers B, Gilbertson D, Herzog C, Johansen K, *et al.* 'United States Renal Data System 2011 Annual Data Report: Atlas of chronic kidney disease & end-stage renal disease in the United States. *Am J Kidney Dis* 2012;59:A7, e1-420.
2. Hwang SJ, Tsai JC, Chen HC. Epidemiology, impact and preventive care of chronic kidney disease in Taiwan. *Nephrology (Carlton)* 2010;15 Suppl 2:3-9.
3. Crawford TN, Alfaro DV, 3rd, Kerrison JB, Jablon EP. Diabetic retinopathy and angiogenesis. *Curr Diabetes Rev* 2009;5:8-13.
4. Maffi P, Secchi A. The Burden of Diabetes: Emerging Data. *Dev Ophthalmol* 2017;60:1-5.
5. Klein BE. Overview of epidemiologic studies of diabetic retinopathy. *Ophthalmic Epidemiol* 2007;14:179-183.
6. Porrini E, Ruggenenti P, Mogensen CE, Barlovic DP, Praga M, Cruzado JM, *et al.* Non-proteinuric pathways in loss of renal function in patients with type 2 diabetes. *Lancet Diabetes Endocrinol* 2015;3:382-391.
7. American Diabetes A. 10. Microvascular Complications and Foot Care. *Diabetes Care* 2017;40:S88-S98.
8. Lee IT, Sheu WH, Lin SY. The Impact of Creatinine Clearance Rate, Daily Urinary Albumin, and Their Joint Effect on Predicting Death in Diabetic Inpatients After Discharge: An Observational Study. *Medicine (Baltimore)* 2016;95:e2804.
9. Porrini E, Ruggenenti P, Mogensen CE, Barlovic DP, Praga M, Cruzado JM, *et al.* Non-proteinuric pathways in loss of renal function in patients with type 2 diabetes. *Lancet Diabetes Endocrinol* 2015;3:382-391.
10. Afkarian M, Zelnick LR, Hall YN, Heagerty PJ, Tuttle K, Weiss NS, *et al.* Clinical Manifestations of Kidney Disease Among US Adults With Diabetes, 1988-2014. *Jama* 2016;316:602-610.
11. Kramer HJ, Nguyen QD, Curhan G, Hsu CY. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. *Jama* 2003;289:3273-3277.
12. Pugliese G. Updating the natural history of diabetic nephropathy. *Acta Diabetol* 2014;51:905-915.
13. Willard AL, Herman IM. Vascular complications and diabetes: current therapies and future challenges. *J Ophthalmol* 2012;2012:209538.
14. Eshaq RS, Aldalati AMZ, Alexander JS, Harris NR. Diabetic retinopathy: Breaking the barrier. *Pathophysiology* 2017;24:229-241.
15. Cheung N, Wang JJ, Klein R, Couper DJ, Sharrett AR, Wong TY. Diabetic retinopathy and the risk of coronary heart disease: the Atherosclerosis Risk in Communities Study.

- 1
2
3 *Diabetes Care* 2007;30:1742-1746.
- 4 16. Xie J, Ikram MK, Cotch MF, Klein B, Varma R, Shaw JE, *et al.* Association of Diabetic
5 Macular Edema and Proliferative Diabetic Retinopathy With Cardiovascular Disease: A
6 Systematic Review and Meta-analysis. *JAMA Ophthalmol* 2017;135:586-593.
- 7 17. Alonso N, Traveset A, Rubinat E, Ortega E, Alcubierre N, Sanahuja J, *et al.* Type 2
8 diabetes-associated carotid plaque burden is increased in patients with retinopathy
9 compared to those without retinopathy. *Cardiovasc Diabetol* 2015;14:33.
- 10 18. Ellis TP, Choudhury RH, Kaul K, Chopra M, Kohner EM, Tarr JM, *et al.* Diabetic
11 retinopathy and atherosclerosis: is there a link? *Curr Diabetes Rev* 2013;9:146-160.
- 12 19. Kramer CK, Rodrigues TC, Canani LH, Gross JL, Azevedo MJ. Diabetic retinopathy
13 predicts all-cause mortality and cardiovascular events in both type 1 and 2 diabetes:
14 meta-analysis of observational studies. *Diabetes Care* 2011;34:1238-1244.
- 15 20. Hsieh YM, Lee WJ, Sheu WH, Li YH, Lin SY, Lee IT. Inpatient screening for
16 albuminuria and retinopathy to predict long-term mortality in type 2 diabetic patients: a
17 retrospective cohort study. *Diabetol Metab Syndr* 2017;9:29.
- 18 21. Torffvit O, Lovestam-Adrian M, Agardh E, Agardh CD. Nephropathy, but not
19 retinopathy, is associated with the development of heart disease in Type 1 diabetes: a
20 12-year observation study of 462 patients. *Diabet Med* 2005;22:723-729.
- 21 22. van Hecke MV, Dekker JM, Stehouwer CD, Polak BC, Fuller JH, Sjolie AK, *et al.*
22 Diabetic retinopathy is associated with mortality and cardiovascular disease incidence:
23 the EURODIAB prospective complications study. *Diabetes Care* 2005;28:1383-1389.
- 24 23. Parving HH, Mogensen CE, Thomas MC, Brenner BM, Cooper ME. Poor prognosis in
25 proteinuric type 2 diabetic patients with retinopathy: insights from the RENAAL study.
26 *Qjm* 2005;98:119-126.
- 27 24. Webster AC, Nagler EV, Morton RL, Masson P. Chronic Kidney Disease. *Lancet*
28 2017;389:1238-1252.
- 29 25. Inker LA, Astor BC, Fox CH, Isakova T, Lash JP, Peralta CA, *et al.* KDOQI US
30 commentary on the 2012 KDIGO clinical practice guideline for the evaluation and
31 management of CKD. *Am J Kidney Dis* 2014;63:713-735.
- 32 26. American Diabetes Association. Standards of medical care in diabetes--2014. *Diabetes*
33 *Care* 2014;37 Suppl 1:S14-80.
- 34 27. Wilkinson CP, Ferris FL, 3rd, Klein RE, Lee PP, Agardh CD, Davis M, *et al.* Proposed
35 international clinical diabetic retinopathy and diabetic macular edema disease severity
36 scales. *Ophthalmology* 2003;110:1677-1682.
- 37 28. Bruno G, Merletti F, Bargerò G, Novelli G, Melis D, Soddu A, *et al.* Estimated
38 glomerular filtration rate, albuminuria and mortality in type 2 diabetes: the Casale
39 Monferrato study. *Diabetologia* 2007;50:941-948.
- 40 29. So WY, Kong AP, Ma RC, Ozaki R, Szeto CC, Chan NN, *et al.* Glomerular filtration rate,
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- cardiorenal end points, and all-cause mortality in type 2 diabetic patients. *Diabetes Care* 2006;29:2046-2052.
30. Wada T, Haneda M, Furuichi K, Babazono T, Yokoyama H, Iseki K, *et al*. Clinical impact of albuminuria and glomerular filtration rate on renal and cardiovascular events, and all-cause mortality in Japanese patients with type 2 diabetes. *Clin Exp Nephrol* 2014;18:613-620.
31. Palsson R, Patel UD. Cardiovascular complications of diabetic kidney disease. *Adv Chronic Kidney Dis* 2014;21:273-280.
32. Toyama T, Furuichi K, Ninomiya T, Shimizu M, Hara A, Iwata Y, *et al*. The impacts of albuminuria and low eGFR on the risk of cardiovascular death, all-cause mortality, and renal events in diabetic patients: meta-analysis. *PLoS One* 2013;8:e71810.
33. Svensson MK, Cederholm J, Eliasson B, Zethelius B, Gudbjornsdottir S. Albuminuria and renal function as predictors of cardiovascular events and mortality in a general population of patients with type 2 diabetes: a nationwide observational study from the Swedish National Diabetes Register. *Diab Vasc Dis Res* 2013;10:520-529.
34. Rigalleau V, Lasseur C, Raffaitin C, Beauvieux MC, Barthe N, Chauveau P, *et al*. Normoalbuminuric renal-insufficient diabetic patients: a lower-risk group. *Diabetes Care* 2007;30:2034-2039.
35. Lee E, Oh HJ, Park JT, Han SH, Ryu DR, Kang SW, *et al*. The Incidence of Cardiovascular Events Is Comparable Between Normoalbuminuric and Albuminuric Diabetic Patients With Chronic Kidney Disease. *Medicine (Baltimore)* 2016;95:e3175.
36. Hsieh YT, Kuo JF, Su SL, Chen JF, Chen HC, Hsieh MC. Subnormal Estimated Glomerular Filtration Rate Strongly Predict Incident Cardiovascular Events in Type 2 Diabetic Chinese Population With Normoalbuminuria. *Medicine (Baltimore)* 2016;95:e2200.
37. Katayama S, Moriya T, Tanaka S, Tanaka S, Yajima Y, Sone H, *et al*. Low transition rate from normo- and low microalbuminuria to proteinuria in Japanese type 2 diabetic individuals: the Japan Diabetes Complications Study (JDCS). *Diabetologia* 2011;54:1025-1031.
38. Ekinci EI, Jerums G, Skene A, Crammer P, Power D, Cheong KY, *et al*. Renal structure in normoalbuminuric and albuminuric patients with type 2 diabetes and impaired renal function. *Diabetes Care* 2013;36:3620-3626.
39. Shimizu M, Furuichi K, Yokoyama H, Toyama T, Iwata Y, Sakai N, *et al*. Kidney lesions in diabetic patients with normoalbuminuric renal insufficiency. *Clin Exp Nephrol* 2014;18:305-312.
40. Thomas MC, Macisaac RJ, Jerums G, Weekes A, Moran J, Shaw JE, *et al*. Nonalbuminuric renal impairment in type 2 diabetic patients and in the general population (national evaluation of the frequency of renal impairment co-existing with

- 1
2
3 NIDDM [NEFRON] 11). *Diabetes Care* 2009;32:1497-1502.
- 4 41. Penno G, Solini A, Bonora E, Fondelli C, Orsi E, Zerbini G, *et al.* Clinical significance
5 of nonalbuminuric renal impairment in type 2 diabetes. *J Hypertens* 2011;29:1802-1809.
- 6 42. Yokoyama H, Sone H, Oishi M, Kawai K, Fukumoto Y, Kobayashi M, *et al.* Prevalence
7 of albuminuria and renal insufficiency and associated clinical factors in type 2 diabetes:
8 the Japan Diabetes Clinical Data Management study (JDDM15). *Nephrol Dial*
9 *Transplant* 2009;24:1212-1219.
- 10 43. Pugliese G, Solini A, Bonora E, Fondelli C, Orsi E, Nicolucci A, *et al.* Chronic kidney
11 disease in type 2 diabetes: lessons from the Renal Insufficiency And Cardiovascular
12 Events (RIACE) Italian Multicentre Study. *Nutr Metab Cardiovasc Dis*
13 2014;24:815-822.
- 14 44. Tanamas SK, Saulnier PJ, Fufaa GD, Wheelock KM, Weil EJ, Hanson RL, *et al.*
15 Long-term Effect of Losartan on Kidney Disease in American Indians With Type 2
16 Diabetes: A Follow-up Analysis of a Randomized Clinical Trial. *Diabetes Care*
17 2016;39:2004-2010.
- 18 45. Penno G, Solini A, Zoppini G, Orsi E, Zerbini G, Trevisan R, *et al.* Rate and
19 determinants of association between advanced retinopathy and chronic kidney disease in
20 patients with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events
21 (RIACE) Italian multicenter study. *Diabetes Care* 2012;35:2317-2323.
- 22 46. Rodriguez-Poncelas A, Mundet-Tuduri X, Miravet-Jimenez S, Casellas A, Barrot-De la
23 Puente JF, Franch-Nadal J, *et al.* Chronic Kidney Disease and Diabetic Retinopathy in
24 Patients with Type 2 Diabetes. *PLoS One* 2016;11:e0149448.
- 25 47. Ricardo AC, Grunwald JE, Parvathaneni S, Goodin S, Ching A, Lash JP. Retinopathy
26 and CKD as predictors of all-cause and cardiovascular mortality: National Health and
27 Nutrition Examination Survey (NHANES) 1988-1994. *Am J Kidney Dis*
28 2014;64:198-203.
- 29 48. Grunwald JE, Pistilli M, Ying GS, Maguire M, Daniel E, Whittock-Martin R, *et al.*
30 Retinopathy and the Risk of Cardiovascular Disease in Patients With Chronic Kidney
31 Disease (from the Chronic Renal Insufficiency Cohort Study). *Am J Cardiol*
32 2015;116:1527-1533.
- 33 49. Semeraro F, Cancarini A, dell'Omo R, Rezzola S, Romano MR, Costagliola C. Diabetic
34 Retinopathy: Vascular and Inflammatory Disease. *J Diabetes Res* 2015;2015:582060.
- 35 50. Chang HW, Li YH, Hsieh CH, Liu PY, Lin GM. Association of body mass index with
36 all-cause mortality in patients with diabetes: a systemic review and meta-analysis.
37 *Cardiovasc Diagn Ther* 2016;6:109-119.
- 38 51. Cea Soriano L, Johansson S, Stefansson B, Rodriguez LA. Cardiovascular events and
39 all-cause mortality in a cohort of 57,946 patients with type 2 diabetes: associations with
40 renal function and cardiovascular risk factors. *Cardiovasc Diabetol* 2015;14:38.
- 41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 52. Pugliese G, Solini A, Fondelli C, Trevisan R, Vedovato M, Nicolucci A, *et al.*
4 Reproducibility of albuminuria in type 2 diabetic subjects. Findings from the Renal
5 Insufficiency And Cardiovascular Events (RIACE) study. *Nephrol Dial Transplant*
6 2011;26:3950-3954.
7
8 53. Karoli R, Fatima J, Shukla V, Garg P, Ali A. Predictors of diabetic retinopathy in patients
9 with type 2 diabetes who have normoalbuminuria. *Ann Med Health Sci Res*
10 2013;3:536-540.
11
12 54. Yoon HE, Kim ES, Mo EY, Shin SJ, Moon SD, Han JH. High normal albuminuria is
13 associated with arterial stiffness and carotid atherosclerosis in Korean patients with type
14 2 diabetes. *Nutr Metab Cardiovasc Dis* 2015;25:787-794.
15
16 55. Salinero-Fort MA, San Andres-Rebollo FJ, de Burgos-Lunar C, Abanades-Herranz JC,
17 Carrillo-de-Santa-Pau E, Chico-Moraleja RM, *et al.* Cardiovascular and all-cause
18 mortality in patients with type 2 diabetes mellitus in the MADIABETES Cohort Study:
19 Association with chronic kidney disease. *J Diabetes Complications* 2016;30:227-236.
20
21 56. Chen LI, Guh JY, Wu KD, Chen YM, Kuo MC, Hwang SJ, *et al.* Modification of diet in
22 renal disease (MDRD) study and CKD epidemiology collaboration (CKD-EPI)
23 equations for Taiwanese adults. *PLoS One* 2014;9:e99645.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. The clinical data of patients according to the presence of CKD and DR

	CKD(-)DR(-) (n = 306)	CKD(-)DR(+) (n = 130)	CKD(+DR(-) (n = 149)	CKD(+DR(+) (n = 80)	P value
Age (years)	57 ± 15	62 ± 13	69 ± 10	70 ± 9	<0.001
Male, n (%)	189 (61.8%)	63 (48.5%)	82 (55.0%)	42 (52.5%)	0.057
BMI (kg/m ²)	23.7 ± 4.5	23.3 ± 4.0	24.2 ± 4.1	24.2 ± 4.3	0.367
Systolic blood pressure (mmHg)	124 ± 14	129 ± 15	127 ± 15	128 ± 14	0.004
Diastolic blood pressure (mmHg)	74 ± 11	75 ± 10	71 ± 9	72 ± 10	0.003
Diabetes duration (years) [#]	6.7 ± 6.7	11.4 ± 7.4	7.9 ± 7.7	13.2 ± 8.4	<0.001
Current smoker, n (%)	96 (31.4%)	36 (27.7%)	31 (20.8%)	13 (16.3%)	0.014
White blood cell count (10 ⁶ /L)	7836 ± 5193	7210 ± 2421	8258 ± 3504	8358 ± 3285	0.227
HbA1c (%)	11.5 ± 2.9	10.6 ± 2.3	10.4 ± 3.3	9.3 ± 2.6	<0.001
Total cholesterol (mmol/L)	4.8 ± 1.3	5.0 ± 1.3	4.6 ± 1.3	4.7 ± 1.5	0.197
Triglyceride (mmol/L) [#]	1.9 ± 1.9	1.9 ± 2.2	2.0 ± 2.2	1.8 ± 1.3	0.574
HDL cholesterol (mmol/L)	1.1 ± 0.4	1.1 ± 0.4	1.0 ± 0.3	1.0 ± 0.4	0.149
eGFR (mL/min/1.73m ²) [#]	88 ± 23	87 ± 20	45 ± 13	42 ± 15	<0.001
Hypertension, n (%)	171 (55.9%)	93 (71.5%)	113 (75.8%)	63 (78.8%)	<0.001
Antihypertensive agents, n (%)	91 (29.7%)	63 (48.5%)	90 (60.4%)	47 (58.8%)	<0.001
ACE inhibitor or ARB, n (%)	58 (19.0%)	44 (33.8%)	59 (39.6%)	32 (40.0%)	<0.001
α-blocker, n (%)	20 (6.5%)	14 (10.8%)	20 (13.4%)	10 (12.5%)	0.079
β-blocker, n (%)	20 (6.5%)	9 (6.9%)	3 (2.0%)	6 (7.5%)	0.172
Calcium channel blocker, n (%)	43 (14.1%)	28 (21.5%)	37 (24.8%)	20 (25.0%)	0.015
Diuretics, n (%)	8 (2.6%)	6 (4.6%)	11 (7.4%)	16 (20.0%)	<0.001
Oral antihyperglycemic drugs, n (%)	151 (49.3%)	65 (50.0%)	53 (35.6%)	27 (33.8%)	0.005
Insulin secretagogues, n (%)	127 (41.5%)	56 (43.1%)	46 (30.9%)	23 (28.8%)	0.027
Metformin, n (%)	95 (31.0%)	41 (31.5%)	26 (17.4%)	17 (21.3%)	0.007

Thiazolidinediones, n (%)	6 (2.0%)	5 (3.8%)	2 (1.3%)	0 (0.0%)	0.230
α -glucosidase inhibitor, n (%)	10 (3.3%)	5 (3.8%)	3 (2.0%)	2 (2.5%)	0.811
Insulin therapy, n (%)	231 (75.5%)	80 (61.5%)	70 (47.0%)	38 (47.5%)	<0.001
Statins, n (%)	28 (9.2%)	12 (9.2%)	17 (11.4%)	12 (15.0%)	0.442

ACE = angiotensin-converting enzyme, ARB = angiotensin II receptor antagonists, BMI = body mass index, CKD = chronic kidney disease, DR = diabetic retinopathy, HbA1c = glycated hemoglobin, HDL = high-density lipoprotein.

Kruskal-Wallis tests to determine the significance of the differences due to skewed distribution in diabetic duration, triglycerides and eGFR

For peer review only

Table 2. Results of Cox regression analysis for the effects of risk factors on (A) all-cause and (B) cardiovascular mortality**(A) All-cause mortality**

	Univariate model			Multivariate model					
	Crude			Model 1			Model 2		
	HR	95%CI	P value	HR	95%CI	P value	HR	95%CI	P value
CKD(-)DR(-)*	1.000			1.000			1.000		
CKD(-)DR(+)	1.590	(1.179, 2.145)	0.002	1.556	(1.148, 2.108)	0.004	1.686	(1.202, 2.364)	0.002
CKD(+DR(-)	1.842	(1.377, 2.463)	<0.001	1.416	(1.042, 1.924)	0.026	1.381	(0.984, 1.939)	0.062
CKD(+DR(+)	2.791	(2.016, 3.866)	<0.001	2.209	(1.573, 3.101)	<0.001	2.263	(1.551, 3.302)	<0.001
Age (every 10 years)	1.455	(1.318, 1.607)	<0.001	1.328	(1.197, 1.472)	<0.001	1.325	(1.177, 1.491)	<0.001
Gender (male)	1.763	(1.394, 2.229)	<0.001	1.763	(1.388, 2.239)	<0.001	1.692	(1.298, 2.206)	<0.001
Current smoker (yes/no)	1.223	(0.958, 1.561)	0.107						
Diabetes duration >7 years (yes/no)	1.271	(1.012, 1.596)	0.039				1.084	(0.832, 1.412)	0.550
BMI (every 1 kg/m ²)	0.959	(0.931, 0.987)	0.004				0.954	(0.925, 0.984)	0.003
Systolic BP (every 10 mmHg)	1.081	(1.002, 1.167)	0.045				1.017	(0.932, 1.111)	0.701
HbA1c (every 1%)	0.969	(0.927, 1.013)	0.163						
Metformin (yes/no)	0.776	(0.604, 0.998)	0.049				0.751	(0.549, 1.028)	0.074
Insulin secretagogues (yes/no)	0.851	(0.677, 1.070)	0.167						
Insulin therapy (yes/no)	0.777	(0.619, 0.974)	0.029				1.094	(0.807, 1.483)	0.562
Statins (yes/no)	1.090	(0.763, 1.557)	0.635						
ACE inhibitor or ARB (yes/no)	1.144	(0.900, 1.454)	0.271						
Calcium channel blocker (yes/no)	1.237	(0.942, 1.625)	0.125						
Diuretics (yes/no)	2.517	(1.714, 3.696)	<0.001				1.765	(1.115, 2.793)	0.015

ACE = angiotensin-converting enzyme, ARB = angiotensin II receptor antagonists, BMI = body mass index, BP = blood pressure, HbA1c = glycated hemoglobin, CI = confidence interval, HR = hazard ratio

The risk factors in the univariate model were selected based on the findings in Table 1.

The risk factors in model 2 were selected based on the statistical significance indicated in the univariate model.

*the overall P value <0.001 among the CKD(-)DR(-), CKD(-)DR(+), CKD(+DR(-), CKD(+DR(+)) groups

(B) Cardiovascular mortality

	Univariate model			Multivariate model					
	Crude			Model 1			Model 2		
	HR	95%CI	P value	HR	95%CI	P value	HR	95%CI	P value
CKD(-)DR(-)*	1.000			1.000			1.000		
CKD(-)DR(+)	2.092	(1.340, 3.267)	0.001	2.039	(1.297, 3.203)	0.002	1.896	(1.153, 3.115)	0.012
CKD(+DR(-)	1.937	(1.221, 3.072)	0.005	1.387	(0.855, 2.251)	0.185	1.376	(0.815, 2.322)	0.232
CKD(+DR(+)	3.601	(2.215, 5.854)	<0.001	2.710	(1.634, 4.493)	<0.001	2.471	(1.421, 4.297)	0.001
Age (every 10 years)	1.615	(1.377, 1.894)	<0.001	1.445	(1.224, 1.706)	<0.001	1.389	(1.152, 1.674)	<0.001
Gender (male)	2.124	(1.472, 3.066)	<0.001	2.132	(1.465, 3.102)	<0.001	2.126	(1.391, 3.250)	<0.001
Current smoker (yes/no)	1.326	(0.922, 1.908)	0.128						
Diabetes duration >7 years (yes/no)	1.775	(1.237, 2.546)	0.002				1.196	(0.788, 1.815)	0.401
BMI (every 1 kg/m ²)	0.885	(0.843, 0.928)	<0.001				0.877	(0.836, 0.921)	<0.001
Systolic BP (every 10 mmHg)	1.157	(1.034, 1.295)	0.011				1.035	(0.912, 1.175)	0.593
HbA1c (every 1%)	0.977	(0.914, 1.045)	0.503						
Metformin (yes/no)	0.819	(0.562, 1.193)	0.297						
Insulin secretagogues (yes/no)	0.950	(0.675, 1.339)	0.771						
Insulin therapy (yes/no)	0.900	(0.635, 1.276)	0.554						
Statins (yes/no)	0.788	(0.425, 1.460)	0.448						
ACE inhibitor or ARB (yes/no)	1.572	(1.113, 2.221)	0.010				1.159	(0.765, 1.756)	0.487
Calcium channel blocker (yes/no)	1.366	(0.914, 2.041)	0.128						
Diuretics (yes/no)	2.387	(1.316, 4.330)	0.004				1.321	(0.618, 2.821)	0.473

ACE = angiotensin-converting enzyme, ARB = angiotensin II receptor antagonists, BMI = body mass index, BP = blood pressure, HbA1c = glycated hemoglobin, CI = confidence interval, HR = hazard ratio

The risk factors in the univariate model were selected based on the findings in Table 1.

The risk factors in model 2 were selected based on the statistical significance indicated in the univariate model.

*the overall P value <0.001 among the CKD(-)DR(-), CKD(-)DR(+), CKD(+DR(-), CKD(+DR(+)




Figure 1.
Flow diagram of enrollment of study subjects with normoalbuminuria.

210x297mm (300 x 300 DPI)





Figure 2.
Kaplan-Meier curves showing survival rates categorized according to chronic kidney disease (CKD) and diabetic retinopathy (DR) in type 2 diabetic inpatients with normoalbuminuria.

210x297mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Supplementary figure.
Receiver operating characteristic (ROC) analysis curves for differentiating normoalbuminuria (urine albumin excretion < 30 mg/day) based on daily urinary protein excretion.

210x297mm (300 x 300 DPI)

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cohort studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1,2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2,3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4,5
Objectives	3	State specific objectives, including any prespecified hypotheses	5
Methods			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	5
		(b) For matched studies, give matching criteria and number of exposed and unexposed	NA
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7
Bias	9	Describe any efforts to address potential sources of bias	14,15
Study size	10	Explain how the study size was arrived at	8
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	7,8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	7,8
		(b) Describe any methods used to examine subgroups and interactions	10
		(c) Explain how missing data were addressed	NA
		(d) If applicable, explain how loss to follow-up was addressed	NA
		(e) Describe any sensitivity analyses	8,9
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	9, Figure 2
		(b) Give reasons for non-participation at each stage	Figure 2
		(c) Consider use of a flow diagram	Figure 2
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Table 1
		(b) Indicate number of participants with missing data for each variable of interest	NA
		(c) Summarise follow-up time (eg, average and total amount)	9
Outcome data	15*	Report numbers of outcome events or summary measures over time	9,10, Figure 2
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Table 2
		(b) Report category boundaries when continuous variables were categorized	11
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	NA
Discussion			
Key results	18	Summarise key results with reference to study objectives	12
Limitations			
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	12-14
Generalisability	21	Discuss the generalisability (external validity) of the study results	12-14
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	14

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Effects of Retinopathy and Chronic Kidney Disease on Long-term Mortality in Type 2 Diabetic Inpatients with Normal Urinary Albumin or Protein: A Retrospective Cohort Study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-021655.R2
Article Type:	Research
Date Submitted by the Author:	06-Jun-2018
Complete List of Authors:	Li, Yu-Hsuan; Taichung Veterans General Hospital, Division of Endocrinology and Metabolism, Department of Internal Medicine Sheu, Wayne; Taichung Veterans General Hospital, Superintendent Lee, I-Te; Taichung Veterans General Hospital, Division of Endocrinology and Metabolism, Department of Internal Medicine
Primary Subject Heading:	Diabetes and endocrinology
Secondary Subject Heading:	Diabetes and endocrinology
Keywords:	Diabetic nephropathy & vascular disease < DIABETES & ENDOCRINOLOGY, Diabetic retinopathy < DIABETES & ENDOCRINOLOGY, Diabetes & endocrinology < INTERNAL MEDICINE

SCHOLARONE™
Manuscripts

Only

1
2
3 **Effects of Retinopathy and Chronic Kidney Disease on Long-term Mortality in Type 2**
4 **Diabetic Inpatients with Normal Urinary Albumin or Protein: A Retrospective Cohort**
5 **Study**
6
7
8
9

10
11 Yu-Hsuan Li ¹, Wayne H-H Sheu ^{1,2}, I-Te Lee ^{1,2,3,*}
12
13

14
15
16 ¹Division of Endocrinology and Metabolism, Department of Internal Medicine, Taichung
17 Veterans General Hospital, Taichung, Taiwan
18

19
20 ² School of Medicine, National Yang-Ming University, Taipei, Taiwan
21

22 ³ School of Medicine, Chung Shan Medical University, Taichung, Taiwan
23
24
25
26

27 **Running title:** DR and CKD in DM with Normoalbuminuria
28
29
30
31

32 ***Correspondence:** I-Te Lee, MD, PhD,
33
34

35 No. 1650 Taiwan Boulevard, Sect. 4, Taichung 40705, Taiwan.
36
37

38 Tel: +886-4-23741300, Fax: +886-4-23741318, E-mail: itlee@vghtc.gov.tw
39
40
41
42

43 ***Correspondence and reprint to:** I-Te Lee MD, PhD. No. 1650 Taiwan Boulevard, Sect. 4,
44 Taichung 40705, Taiwan.
45
46

47 E-mail: itlee@vghtc.gov.tw
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objective: Normoalbuminuric chronic kidney disease (NA-CKD) is recognized as a distinct phenotype of diabetic kidney disease, but the role of diabetic retinopathy (DR) in predicting long-term mortality among these patients remains unclear. Here, we aimed to investigate the effects of DR and chronic kidney disease (CKD) on mortality in type 2 diabetic patients with normoalbuminuria.

Design: We conducted this study as a retrospective cohort study.

Setting: We collected clinical information from the medical records of a public medical center in central Taiwan.

Participants: Patients with type 2 diabetes (n = 665) who were hospitalized due to poor glucose control were consecutively enrolled and followed for a median of 6.7 years (interquartile range, 4.1–9.6 years). Patients with either urinary protein excretion >150 mg/day or urine albumin excretion >30 mg/day were excluded.

Primary outcome measure: All-cause mortality served as the primary follow-up outcome, and the mortality data were obtained from the national registry in Taiwan.

Results: The patients with CKD and DR showed the highest mortality rate (log-rank $P < 0.001$). The risks of all-cause mortality (hazard ratio [HR], 2.263; 95% confidence interval [CI], 1.551–3.302) and cardiovascular mortality (HR, 2.471; 95% CI, 1.421–4.297) were significantly greater in patients with CKD and DR than in those without CKD or DR, after

1
2
3
4 adjusting for the associated risk factors.
5

6 **Conclusions:** DR is an independent predictor for all-cause and cardiovascular mortality in
7
8
9 type 2 diabetic inpatients with normoalbuminuria. Moreover, DR with CKD shows the
10
11
12 highest risks of all-cause and cardiovascular mortality among these patients. Fundoscopy
13
14
15 screening can provide additive information on mortality in patients with type 2 diabetes,
16
17
18 even among those with NA-CKD.
19
20
21
22

23 **Strengths and limitations of this study**

- 24
25
26
27 ■ Twenty-four hour urine collection during the hospitalization period
28
29
- 30
31 ■ A median follow-up period of 6.7 years
32
33
- 34
35 ■ Mortality data obtained from a National Health Insurance registry with a nationwide
36
37 coverage rate of over 99% in Taiwan
38
39
- 40
41 ■ In addition to normoalbuminuria, normoproteinuria was also included in the analyses
42
43
44 due to limited case numbers
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

Diabetes is associated with microvascular complications, and is the leading cause of both end-stage renal disease (ESRD) and blindness.¹⁻⁵ Diabetic kidney disease (DKD) is a complex and heterogeneous disease, particularly among patients with type 2 diabetes.⁶ The urinary albumin level is an important biomarker for DKD,⁷ and is predictive of all-cause and cardiovascular mortality.^{8,9} Extensive resources and efforts have focused on understanding and preventing albuminuria, and its prevalence has consequently been significantly reduced; however, the prevalence of low estimated glomerular filtration rate (eGFR) has still increased among patients with diabetes.¹⁰

Normoalbuminuria was reported in 36% of type 2 diabetic patients with CKD in the Third National Health and Nutrition Examination Survey (NHANES) 1988–1994,¹¹ and was reported in 48.1 % of diabetic patients with CKD in the NHANES 2005–2008.¹⁰ The prevalence of normoalbuminuria in CKD appears to have increased over the 15 years.^{10,11} With the recent progress in the management of diabetic complications, it appears that this paradigm has shifted, and the phenotype of normoalbuminuric chronic kidney disease (NA-CKD) has emerged.^{6,12} Hence, the mechanism by which NA-CKD leads to cardiovascular disease and mortality remains a popular area of research.

Diabetic retinopathy (DR) has been traditionally recognized as an early reflection of general microangiopathy in patients with type 2 diabetes.^{3,13,14} Accumulating evidence has

1
2
3
4 shown that DR is a predictor of cardiovascular disease and all-cause mortality in subjects
5
6 with type 2 diabetes.¹⁵⁻¹⁸ However, some studies have reported that DR is not predictive of
7
8 mortality in the presence of DKD,^{19 20} and the association between DR and cardiovascular
9
10 disease becomes non-significant after adjusting for the albuminuria.²¹⁻²³
11
12
13

14
15 In the present study, we aimed to investigate the mortality risk among type 2 diabetic
16
17 patients without albuminuria, and we hypothesized that DR was predictive of long-term
18
19 mortality in type 2 diabetic patients with NA-CKD or without NA-CKD.
20
21
22
23
24
25

26 **METHODS**

27 *Setting and participants*

28
29 This retrospective cohort study was conducted at Taichung Veterans General Hospital.
30
31
32 Clinical data were obtained by reviewing the medical records of diabetic patients hospitalized
33
34 between August 1996 and August 2007. The inclusion criteria were (1) adult diabetic
35
36 inpatients based on the clinical diagnosis, (2) admission to the Endocrinology and
37
38 Metabolism section due to a primary diagnosis of poor glucose control, (3) availability of
39
40 eGFR data, and (4) performance of 24-hour urine collection for the determination of albumin
41
42 or protein levels during the hospitalization period. The exclusion criteria included (1) urinary
43
44 protein excretion ≥ 150 mg/day or urine albumin excretion ≥ 30 mg/day,²⁴ (2) death during
45
46 this hospitalization period, (3) systolic blood pressure < 90 mmHg, (4) urine volume < 300
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 ml/day, (5) diagnosis of diabetes other than type 2, and (6) the unavailability of reports
4
5
6 documenting eye fundal examinations for retinopathy by an ophthalmologist during the
7
8
9 hospitalization period. In repeatedly hospitalized patients, data recorded from the last
10
11
12 admission during the study period were used. The research protocol was approved by the
13
14
15 Institutional Review Board of Taichung Veterans General Hospital.

16 17 18 19 20 *Patient and Public Involvement*

21
22
23 All-cause mortality served as the primary outcome in this retrospective cohort study, and
24
25
26 the mortality data were obtained from the national registry in Taiwan. We collected clinical
27
28
29 information from the medical records at Taichung Veterans General Hospital. The
30
31
32 Institutional Review Board waived the need for informed consent before reviewing the
33
34
35 medical records.

36 37 38 39 40 *Variables*

41
42
43 A normal urinary albumin level was defined as 24-hour urine albumin excretion <
44
45
46 30mg.²⁴⁻²⁶ In those inpatients with only protein detected, however, normal urine protein was
47
48
49 defined as 24-hour urine protein < 150 mg.²⁴ CKD was defined as an eGFR < 60
50
51
52 mL/min/1.73m². The eGFR was calculated by the Modification of Diet in Renal Disease
53
54
55 (MDRD) equation: $186 \times [\text{serum creatinine (mg/dL)}]^{-1.154} \times [\text{age (year)}]^{-0.203} (\times 0.742, \text{ if}$

1
2
3 female) mL/min/1.73m².²⁵
4
5

6 DR includes nonproliferative diabetic retinopathy (NPDR) and proliferative diabetic
7 retinopathy (PDR).²⁷ DR was screened using fundoscopic examinations by ophthalmologists
8 based on formal consultations. Retinal angiography (CF-60UVi fundus camera, Canon, Japan)
9 was subsequently arranged for the confirmation of retinopathy diagnosis in cases with
10 abnormal fundoscopic findings. Hypertension was defined as blood pressure higher than
11 130/80 mmHg or a history of anti-hypertensive medications use. After medical information
12 was collected from our hospital, we also obtained the mortality data up to December 2011
13 from the Collaboration Center of Health Information Application, Department of Health,
14 Executive Yuan, Taiwan. The causes of death were categorized according to the International
15 Classification of Disease (ICD), 9th Revision, Clinical Modification diagnostic criteria before
16 2008 and according to the ICD-10 after 01 January, 2008.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42

43 *Measurement*

44 Biochemistry was assessed from blood samples collected after overnight fasting during
45 the hospitalization period. HbA1c levels were determined using cation-exchange HPLC
46 (NGSP certified; G8, TOSOH, Tokyo, Japan). Lipid levels were determined using
47 enzymatic methods (Advia 1800, Siemens, New York, USA). Creatinine levels were
48 determined using the Jaffé method (Advia 1800, Siemens, New York, USA). Urine protein
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 levels were determined using the dye-binding assay, and urine albumin levels were assessed
5
6 using the immune-turbidimetric method (Advia 1800, Siemens, New York, USA).
7
8
9

10 11 12 *Comparison of cutoff values of daily urinary protein excretion for normoalbuminuria* 13

14
15 Among the 2482 diabetic inpatients who had undergone 24-hour urine collection, only
16
17 245 had the data for both urine albumin and protein levels in the same urine sample. The
18
19 median level of daily protein excretion was 184 mg (interquartile range, 80–620 mg) and the
20
21 median level of daily albumin excretion was 58 mg (interquartile range, 15–362 mg). There
22
23 was a significant positive correlation between daily urine protein and albumin excretion ($r =$
24
25 0.884, $P < 0.001$). Receiver operating characteristic (ROC) curves were used to differentiate
26
27 normal urine albumin excretion (<30 mg/day), and we found that the area under the curve
28
29 was 0.956 (95% confidence interval [CI], 0.932–0.979; $P < 0.001$; supplementary figure).
30
31
32 The optimal diagnostic cutoff value for the daily urine protein level was 145 mg, which
33
34 corresponded to a sensitivity of 93.8% and specificity of 86.5% for normoalbuminuria. Using
35
36 150 mg as diagnostic cutoff value of daily urine protein also gave a sensitivity of 93.8% and
37
38 specificity of 86.5% for normoalbuminuria.
39
40
41
42
43
44
45
46
47
48
49
50
51

52 *Statistical analysis* 53

54 Continuous data are presented as mean \pm standard deviation (SD), whereas categorical
55
56
57
58
59
60

1
2
3
4 data are presented as number (n) with percentage (%). The linear correlation of daily
5
6 excretion between urine protein and albumin was determined using Spearman's rank
7
8 correlation coefficient. The ROC curve was used to determine the optimal cut-off value of
9
10 daily urine protein for normoalbuminuria. One-way analysis of variance (ANOVA) was used
11
12 to determine the significance of the differences among groups. Pairwise multiple comparisons
13
14 were conducted to determine the significance of the differences between two groups, if a
15
16 statistically significant difference was detected via one-way ANOVA; however,
17
18 Kruskal-Wallis tests were conducted to determine the significance of the differences in the
19
20 duration of diabetes, triglycerides levels and eGFR values among groups due to the presence
21
22 of a skewed distribution in these variables. The Chi-square test was used to compare
23
24 categorical variables across groups. The overall significance of univariate survival analysis
25
26 was determined by the log-rank test using Kaplan-Meier analysis. Cox proportional hazards
27
28 regression analyses were conducted to determine the hazard ratios of risk factors. The risk
29
30 factors in the univariate model were selected based on the findings in Table 1, whereas the
31
32 risk factors in model 2 were selected based on the statistical significance indicated in the
33
34 univariate model. Except the inclusion and exclusion criteria, the mean imputation method
35
36 was used for missing data. A value of $P < 0.05$ was considered statistically significant.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51 Statistical analysis was performed using SPSS 22.0 (IBM, Armonk, NY, USA).
52
53
54
55
56
57
58
59
60

RESULTS

Comparison of the outcomes between patients with and without fundal examination

A total of 665 patients with a median diabetes duration of 7 years (interquartile range, 2–12 years) met the criteria for enrollment in the study and were included in these analyses (figure 1). In comparison with the 238 patients who were eligible for all the criteria except for lacking a fundal examination for retinopathy, there were no statically significant differences in age (62 ± 14 vs. 63 ± 15 years, $P = 0.777$), gender (56.5% men vs. 61.3% men, $P = 0.226$), diabetes duration (8.7 ± 7.7 vs. 8.9 ± 8.6 years, $P = 0.789$), eGFR (73 ± 29 vs. 71 ± 30 mL/min/1.73m², $P = 0.642$), all-cause mortality incidence (6.6 vs. 6.5 events/100 person-years, log-rank test $P = 0.888$), and cardiovascular mortality (2.9 vs. 2.9 events/100 person-years, log-rank test $P = 0.965$).

Risk of long-term mortality in CKD or DR in patients with normoalbuminuria

There were 229 (34.4%) patients with CKD and 210 (31.6%) with DR in the 665 enrolled type 2 diabetic inpatients with normoalbuminuria. During a median follow-up of 6.7 years (interquartile range, 4.1–9.6years), 315 (47.4%) patients died from any cause; in particular, 138 patients died of cardiovascular disease (figure 1). The all-cause mortality rate was higher in the patients with CKD than in those without CKD (9.4 vs. 5.4 events/100 person-years, log-rank test $P < 0.001$); and the all-cause mortality rate was also higher in the

1
2
3 patients with DR than those without DR (9.0 vs. 5.6 events/100 person-years, log-rank test P
4
5 < 0.001). Moreover, the cardiovascular mortality rate was higher in patients with CKD than
6
7 in those without CKD (4.2 vs. 2.4 events/100 person-years, log-rank test P < 0.001); this rate
8
9 was also higher in patients with DR than in those without DR (4.5 vs. 2.2 events/100
10
11 person-years, log-rank test P < 0.001).
12
13
14
15
16
17
18
19

20 *A combined effect of retinopathy and CKD on long-term mortality*

21
22
23 The proportion of patients with DR was not significantly different between the patients
24
25 with CKD and those without CKD (34.9% vs. 29.8%, P = 0.207). The 665 patients were
26
27 separated into four groups based on the presence of CKD and DR, including (1) patients
28
29 without CKD or DR in the CKD(-)DR(-) group, (2) patients with DR but not CKD in the
30
31 CKD(-)DR(+) group, (3) patients with CKD but not DR in the CKD(+)DR(-) group, and (4)
32
33 patients with both CKD and DR in the CKD(+)DR(+) group. Table 1 shows all the clinical
34
35 characteristics of patients among these four groups. Figure 2 shows that survival rates were
36
37 significantly different across these four groups (log-rank test P < 0.001), as demonstrated by
38
39 Kaplan–Meier analysis. The highest mortality incidence (12.4 events/100 person-years) was
40
41 observed in the CKD(+)DR(+) group; this value was significantly higher than the 8.1
42
43 events/100 person-years in the CKD(+)DR(-) group (P = 0.010), the 7.4 events/100
44
45 person-years in the CKD(-)DR(+) group (P = 0.004), and the 4.6 events/100 person-years in
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 the CKD(-)DR(-) group ($P < 0.001$). The incidences of mortality in the CKD(+)DR(-) and
4
5
6 CKD(-)DR(+) groups were also significantly higher than that in the CKD(-)DR(-) group (P
7
8
9 < 0.001 and $P = 0.003$, respectively). However, there was no significant difference in the
10
11
12 mortality incidence between the CKD(+)DR(-) and CKD(-)DR(+) groups ($P = 0.479$).
13
14
15

16 17 *Cox regression analysis for all-cause and cardiovascular mortality*

18
19
20 To identify the predictive factors for long-term mortality, univariate Cox regression
21
22
23 analysis was conducted for all the enrolled patients. In addition to the different groups
24
25
26 categorized based on CKD and DR, age, gender, diabetes duration, body mass index (BMI),
27
28
29 systolic blood pressure, metformin treatment, insulin treatment, and diuretic treatment were
30
31
32 significantly associated with total mortality. Using multivariate Cox regression analysis,
33
34
35 patients with CKD and DR have the highest hazard ratio (2.263; 95% CI, 1.551–3.302) for
36
37
38 all-cause mortality in comparison with the ones without CKD or DR after adjustment for age,
39
40
41 gender, diabetes duration, BMI, systolic blood pressure, metformin treatment, insulin
42
43
44 treatment and diuretics treatment (Table 2A). Moreover, patients with CKD and DR also had
45
46
47 the highest hazard ratio (2.471; 95% CI, 1.421–4.297) for cardiovascular mortality in
48
49
50 comparison to the ones without CKD or DR after adjustment for age, gender, diabetes
51
52
53 duration, BMI, systolic blood pressure and angiotensin-converting enzyme (ACE) inhibitor or
54
55
56 angiotensin II receptor antagonist (ARB) treatment (Table 2B).
57
58
59
60

DISCUSSION

In this retrospective cohort study, we found that patients with NA-CKD have a higher risk of all-cause mortality compared with patients without CKD. Furthermore, the presence of DR imposed a higher mortality risk in patients with NA-CKD.

The mortality risk associated with NA-CKD remains controversial. In the Casale Monferrato study, which had an 11-year follow-up, eGFR showed a significantly inverse trend with long-term mortality only in type 2 diabetic patients with macroalbuminuria, but not in those with microalbuminuria or normoalbuminuria.²⁸ Conversely, several studies reported that low eGFR was significantly associated with a higher all-cause mortality risk, independent of albuminuria.²⁹⁻³³ The magnitude of the impact on all-cause mortality varied. Rigalleau et al.³⁴ reported that NA-CKD was associated with a very low risk of dialysis or mortality in comparison with albuminuric CKD in diabetic patients during a 38-month follow-up study in France. In an Asian study with a 44-month follow-up, albuminuria was associated with a significantly higher risk of renal events, but not cardiovascular events in diabetic patients with CKD.³⁵ In the present study, we found that NA-CKD is associated with an approximately 1.8-fold increase in either all-cause mortality or cardiovascular disease, compared with type 2 diabetic patients without CKD. In line with our findings, Hsieh et al.³⁶ reported that eGFR was inversely related to risk of cardiovascular events in type 2 diabetic

1
2
3
4 outpatients with normoalbuminuria during a 4-year follow-up study.
5

6 We postulated that heterogeneity in the pathogenesis of NA-CKD might contribute to
7
8 the differences in results. Different natural courses have been observed in the NA-CKD
9
10 phenotype: initial albuminuria with regression to normoalbuminuria with intensive
11
12 renin-angiotensin-aldosterone system (RAAS) inhibitor use in some diabetic patients, but
13
14 eGFR loss might be the only manifestation of renal involvement in others.^{12,37} Based on renal
15
16 biopsy, tubular-interstitial lesions and arterial hyalinosis were the predominant findings in
17
18 NA-CKD rather than the typical glomerulosclerotic lesions seen with albuminuria in diabetic
19
20 patients.^{38,39} With albuminuria regression due to the widespread use of RAAS inhibitors in
21
22 recent decades, NA-CKD is being found in majority of DKD patients. The number of patients
23
24 with normoalbuminuria has been found to be great than those with albuminuria in several
25
26 large studies of type 2 diabetic patients with CKD.⁴⁰⁻⁴² Hence, there is an urgent need to
27
28 identify the predictors of mortality among this distinct population.⁴³
29
30
31
32
33
34
35
36
37
38
39

40 In the present study, patients using ACE inhibitors or ARBs showed a higher risk of
41
42 cardiovascular mortality in the univariate model, and this finding may result from the higher
43
44 proportion of CKD patients using these drugs at baseline. In the multivariate model, the use
45
46 of ACE inhibitors or ARBs at baseline was not significantly associated with cardiovascular
47
48 mortality. Consistent with these findings, early ARB treatment was not found to significantly
49
50 improve eGFR in type 2 diabetic patients with urine albumin-to-creatinine ratio <300 mg/g.⁴⁴
51
52
53
54
55
56
57
58
59
60

1
2
3
4 Although there is a high prevalence of DR in type 2 diabetic patients with albuminuria,²⁰
5
6 the concordance between DR and CKD was lower in patients with normoalbuminuria than in
7
8 those with albuminuria.^{45 46} In the present study, we found that the prevalence of retinopathy
9
10 was not significantly different between patients with and without CKD. However, the highest
11
12 risks of all-cause mortality and cardiovascular mortality were shown in the patients with
13
14 CKD and DR. Compared with the NEHANS III population, in which the synergistic effect of
15
16 CKD and retinopathy on mortality was also observed,⁴⁷ our findings showed the evidence in
17
18 type 2 diabetic inpatients even without albuminuria. Although similar risk factors and
19
20 cardiovascular effects for DR and CKD have been reported,^{30 48 49} the exact mechanism
21
22 underlying the superimposed DR effect on mortality in type 2 diabetic patients with
23
24 NA-CKD requires further investigation.
25
26
27
28
29
30
31
32
33

34 In the present study, both isolated CKD, i.e. CKD(+)DR(-), and isolated DR, i.e.
35
36 CKD(-)DR(+), showed significantly higher mortality risks than those with neither CKD nor
37
38 DR in univariate analyses; however, the significant difference seemed to attenuate in isolated
39
40 CKD after adjustment for other traditional cardiovascular risk factors. NA-CKD has been
41
42 reported to be highly associated with cardiovascular risk factors.^{36 42} Therefore, the
43
44 attenuation of the mortality prediction after adjustment for cardiovascular risk factors might
45
46 be more obvious in isolated CKD in comparison with isolated DR. Furthermore, it is notable
47
48 that a higher BMI showed a protective effect for all-cause and cardiovascular mortality in the
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 present study. Although this seems somewhat contradictory to traditional concepts, we were
5
6 not the only one to report this paradoxical effect of BMI on mortality in patients with
7
8 diabetes.⁵⁰ Cea Soriano et al.⁵¹ reported that $\text{BMI} \geq 25 \text{ kg/m}^2$ predicted a lower mortality risk
9
10 than $\text{BMI} < 25 \text{ kg/m}^2$ in type 2 diabetic patients with CKD.
11
12
13

14
15 Among type 2 diabetic patients with normoalbuminuria, high urine albumin excretion
16
17 (10–29 mg/day) was reportedly associated with multiple cardiovascular risk factors, as
18
19 compared to low urine albumin excretion ($< 10 \text{ mg/day}$).⁵² Recently, the highest tertile of the
20
21 urine albumin excretion rate was found to be associated with diabetic retinopathy and arterial
22
23 stiffness, in comparison to the lowest tertile among type 2 diabetic patients with
24
25 normoalbuminuria.^{53 54} In the present study, 257 patients without CKD had available urine
26
27 albumin data, including 108 patients with low normoalbuminuria ($< 10 \text{ mg/day}$) and 149
28
29 patients with high normoalbuminuria (10–29 mg/day). However, there was no significant
30
31 difference in DR prevalence ($P > 0.05$) or all-cause and cardiovascular mortality (both
32
33 log-rank test $P > 0.05$). Further investigations with a large number of cases will be needed to
34
35 evaluate the association between high normoalbuminuria and mortality.
36
37
38
39
40
41
42
43
44
45

46 We acknowledge several limitations in our study. First, we enrolled patients with not
47
48 only normoalbuminuria, but also normoproteinuria, due to the limited numbers of cases
49
50 overall. Second, we used the 24-hour urine data instead of spot-urine data, since the latter has
51
52 been well reported in type 2 outpatients previously.⁵⁵ Third, we only included type 2 diabetic
53
54
55
56
57
58
59
60

1
2
3
4 inpatients who were admitted to the hospital with a primary diagnosis of poor glucose control.

5
6 Fourth, we calculated eGFR using the MDRD equation instead of the CKD Epidemiology
7
8
9 Collaboration (EPI) equation as consensus had not been reached regarding the use of the
10
11
12 CKD-EPI equation in the Taiwanese population.⁵⁶ Finally, we assessed the patients only at
13
14
15 baseline, but not during the follow-up. Therefore, treatment might have confounded the
16
17
18 results following patients discharged.

19
20 In conclusion, DR is a significant predictor for all-cause and cardiovascular mortality in
21
22
23 type 2 diabetic inpatients with normoalbuminuria. Presence of DR also showed an impact on
24
25
26 mortality for type 2 diabetic inpatients with NA-CKD. Screening for DR and eGFR may help
27
28
29 identify those who harbor a high mortality risk after discharge in type 2 diabetic inpatients
30
31
32 hospitalized due to poor glucose control, even with normoalbuminuria.

33
34
35
36
37 **Funding:** This work was supported by Taichung Veterans General Hospital, Taichung,
38
39
40 Taiwan (grant number TCVGH-TCVGH-1063501E, TCVGH-1063502C), and the Ministry
41
42
43 of Science and Technology, Taiwan (grant number MOST 105-2314-B-075A-003). The
44
45
46 funders had no role in the decision to submit the manuscript for publication.

47
48
49
50
51 **Acknowledgments:** Mortality data were provided by the Collaboration Center of Health
52
53
54 Information Application, Ministry of Health and Welfare, Executive Yuan. The statistical
55
56
57

1
2
3
4 analysis was performed by the Biostatistics Task Force of Taichung Veterans General
5
6 Hospital, Taichung, Taiwan.
7
8
9
10
11

12 **Competing interests:** The authors declare that they have no competing interests to declare.
13
14
15

16
17
18 **Data sharing statement:** No additional data are available.
19
20
21
22

23 **Author contributions**

24
25
26 YL, WHS and IL contributed to the study design. YL and IL participated in the data
27
28 collection. YL and IL participated in the analysis and interpretation of the data. YL drafted the
29
30 manuscript. IL had full access to the study data. IL is the guarantor. All the authors performed
31
32 a critical revision of the manuscript for important intellectual content.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 **FIGURE LEGENDS**
5

6 **Figure 1.** Flow diagram of enrollment of study subjects with normoalbuminuria.
7

8
9 **Figure 2.** Kaplan-Meier curves showing survival rates categorized according to chronic
10 kidney disease (CKD) and diabetic retinopathy (DR) in type 2 diabetic inpatients with
11
12
13
14
15 normoalbuminuria.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Collins AJ, Foley RN, Chavers B, Gilbertson D, Herzog C, Johansen K, *et al.* 'United States Renal Data System 2011 Annual Data Report: Atlas of chronic kidney disease & end-stage renal disease in the United States. *Am J Kidney Dis* 2012;59:A7, e1-420.
2. Hwang SJ, Tsai JC, Chen HC. Epidemiology, impact and preventive care of chronic kidney disease in Taiwan. *Nephrology (Carlton)* 2010;15 Suppl 2:3-9.
3. Crawford TN, Alfaro DV, 3rd, Kerrison JB, Jablon EP. Diabetic retinopathy and angiogenesis. *Curr Diabetes Rev* 2009;5:8-13.
4. Maffi P, Secchi A. The Burden of Diabetes: Emerging Data. *Dev Ophthalmol* 2017;60:1-5.
5. Klein BE. Overview of epidemiologic studies of diabetic retinopathy. *Ophthalmic Epidemiol* 2007;14:179-183.
6. Porrini E, Ruggenenti P, Mogensen CE, Barlovic DP, Praga M, Cruzado JM, *et al.* Non-proteinuric pathways in loss of renal function in patients with type 2 diabetes. *Lancet Diabetes Endocrinol* 2015;3:382-391.
7. American Diabetes A. 10. Microvascular Complications and Foot Care. *Diabetes Care* 2017;40:S88-S98.
8. Lee IT, Sheu WH, Lin SY. The Impact of Creatinine Clearance Rate, Daily Urinary Albumin, and Their Joint Effect on Predicting Death in Diabetic Inpatients After Discharge: An Observational Study. *Medicine (Baltimore)* 2016;95:e2804.
9. Porrini E, Ruggenenti P, Mogensen CE, Barlovic DP, Praga M, Cruzado JM, *et al.* Non-proteinuric pathways in loss of renal function in patients with type 2 diabetes. *Lancet Diabetes Endocrinol* 2015;3:382-391.
10. Afkarian M, Zelnick LR, Hall YN, Heagerty PJ, Tuttle K, Weiss NS, *et al.* Clinical Manifestations of Kidney Disease Among US Adults With Diabetes, 1988-2014. *Jama* 2016;316:602-610.
11. Kramer HJ, Nguyen QD, Curhan G, Hsu CY. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. *Jama* 2003;289:3273-3277.
12. Pugliese G. Updating the natural history of diabetic nephropathy. *Acta Diabetol* 2014;51:905-915.
13. Willard AL, Herman IM. Vascular complications and diabetes: current therapies and future challenges. *J Ophthalmol* 2012;2012:209538.
14. Eshaq RS, Aldalati AMZ, Alexander JS, Harris NR. Diabetic retinopathy: Breaking the barrier. *Pathophysiology* 2017;24:229-241.
15. Cheung N, Wang JJ, Klein R, Couper DJ, Sharrett AR, Wong TY. Diabetic retinopathy and the risk of coronary heart disease: the Atherosclerosis Risk in Communities Study.

- 1
2
3 *Diabetes Care* 2007;30:1742-1746.
- 4 16. Xie J, Ikram MK, Cotch MF, Klein B, Varma R, Shaw JE, *et al.* Association of Diabetic
5 Macular Edema and Proliferative Diabetic Retinopathy With Cardiovascular Disease: A
6 Systematic Review and Meta-analysis. *JAMA Ophthalmol* 2017;135:586-593.
- 7
8 17. Alonso N, Traveset A, Rubinat E, Ortega E, Alcubierre N, Sanahuja J, *et al.* Type 2
9 diabetes-associated carotid plaque burden is increased in patients with retinopathy
10 compared to those without retinopathy. *Cardiovasc Diabetol* 2015;14:33.
- 11
12 18. Ellis TP, Choudhury RH, Kaul K, Chopra M, Kohner EM, Tarr JM, *et al.* Diabetic
13 retinopathy and atherosclerosis: is there a link? *Curr Diabetes Rev* 2013;9:146-160.
- 14
15 19. Kramer CK, Rodrigues TC, Canani LH, Gross JL, Azevedo MJ. Diabetic retinopathy
16 predicts all-cause mortality and cardiovascular events in both type 1 and 2 diabetes:
17 meta-analysis of observational studies. *Diabetes Care* 2011;34:1238-1244.
- 18
19 20. Hsieh YM, Lee WJ, Sheu WH, Li YH, Lin SY, Lee IT. Inpatient screening for
20 albuminuria and retinopathy to predict long-term mortality in type 2 diabetic patients: a
21 retrospective cohort study. *Diabetol Metab Syndr* 2017;9:29.
- 22
23 21. Torffvit O, Lovestam-Adrian M, Agardh E, Agardh CD. Nephropathy, but not
24 retinopathy, is associated with the development of heart disease in Type 1 diabetes: a
25 12-year observation study of 462 patients. *Diabet Med* 2005;22:723-729.
- 26
27 22. van Hecke MV, Dekker JM, Stehouwer CD, Polak BC, Fuller JH, Sjolie AK, *et al.*
28 Diabetic retinopathy is associated with mortality and cardiovascular disease incidence:
29 the EURODIAB prospective complications study. *Diabetes Care* 2005;28:1383-1389.
- 30
31 23. Parving HH, Mogensen CE, Thomas MC, Brenner BM, Cooper ME. Poor prognosis in
32 proteinuric type 2 diabetic patients with retinopathy: insights from the RENAAL study.
33 *Qjm* 2005;98:119-126.
- 34
35 24. Webster AC, Nagler EV, Morton RL, Masson P. Chronic Kidney Disease. *Lancet*
36 2017;389:1238-1252.
- 37
38 25. Inker LA, Astor BC, Fox CH, Isakova T, Lash JP, Peralta CA, *et al.* KDOQI US
39 commentary on the 2012 KDIGO clinical practice guideline for the evaluation and
40 management of CKD. *Am J Kidney Dis* 2014;63:713-735.
- 41
42 26. American Diabetes Association. Standards of medical care in diabetes--2014. *Diabetes*
43 *Care* 2014;37 Suppl 1:S14-80.
- 44
45 27. Wilkinson CP, Ferris FL, 3rd, Klein RE, Lee PP, Agardh CD, Davis M, *et al.* Proposed
46 international clinical diabetic retinopathy and diabetic macular edema disease severity
47 scales. *Ophthalmology* 2003;110:1677-1682.
- 48
49 28. Bruno G, Merletti F, Bargerò G, Novelli G, Melis D, Soddu A, *et al.* Estimated
50 glomerular filtration rate, albuminuria and mortality in type 2 diabetes: the Casale
51 Monferrato study. *Diabetologia* 2007;50:941-948.
- 52
53 29. So WY, Kong AP, Ma RC, Ozaki R, Szeto CC, Chan NN, *et al.* Glomerular filtration rate,
54
55
56
57
58
59

- cardiorenal end points, and all-cause mortality in type 2 diabetic patients. *Diabetes Care* 2006;29:2046-2052.
30. Wada T, Haneda M, Furuichi K, Babazono T, Yokoyama H, Iseki K, *et al*. Clinical impact of albuminuria and glomerular filtration rate on renal and cardiovascular events, and all-cause mortality in Japanese patients with type 2 diabetes. *Clin Exp Nephrol* 2014;18:613-620.
31. Palsson R, Patel UD. Cardiovascular complications of diabetic kidney disease. *Adv Chronic Kidney Dis* 2014;21:273-280.
32. Toyama T, Furuichi K, Ninomiya T, Shimizu M, Hara A, Iwata Y, *et al*. The impacts of albuminuria and low eGFR on the risk of cardiovascular death, all-cause mortality, and renal events in diabetic patients: meta-analysis. *PLoS One* 2013;8:e71810.
33. Svensson MK, Cederholm J, Eliasson B, Zethelius B, Gudbjornsdottir S. Albuminuria and renal function as predictors of cardiovascular events and mortality in a general population of patients with type 2 diabetes: a nationwide observational study from the Swedish National Diabetes Register. *Diab Vasc Dis Res* 2013;10:520-529.
34. Rigalleau V, Lasseur C, Raffaitin C, Beauvieux MC, Barthe N, Chauveau P, *et al*. Normoalbuminuric renal-insufficient diabetic patients: a lower-risk group. *Diabetes Care* 2007;30:2034-2039.
35. Lee E, Oh HJ, Park JT, Han SH, Ryu DR, Kang SW, *et al*. The Incidence of Cardiovascular Events Is Comparable Between Normoalbuminuric and Albuminuric Diabetic Patients With Chronic Kidney Disease. *Medicine (Baltimore)* 2016;95:e3175.
36. Hsieh YT, Kuo JF, Su SL, Chen JF, Chen HC, Hsieh MC. Subnormal Estimated Glomerular Filtration Rate Strongly Predict Incident Cardiovascular Events in Type 2 Diabetic Chinese Population With Normoalbuminuria. *Medicine (Baltimore)* 2016;95:e2200.
37. Katayama S, Moriya T, Tanaka S, Tanaka S, Yajima Y, Sone H, *et al*. Low transition rate from normo- and low microalbuminuria to proteinuria in Japanese type 2 diabetic individuals: the Japan Diabetes Complications Study (JDCS). *Diabetologia* 2011;54:1025-1031.
38. Ekinci EI, Jerums G, Skene A, Crammer P, Power D, Cheong KY, *et al*. Renal structure in normoalbuminuric and albuminuric patients with type 2 diabetes and impaired renal function. *Diabetes Care* 2013;36:3620-3626.
39. Shimizu M, Furuichi K, Yokoyama H, Toyama T, Iwata Y, Sakai N, *et al*. Kidney lesions in diabetic patients with normoalbuminuric renal insufficiency. *Clin Exp Nephrol* 2014;18:305-312.
40. Thomas MC, Macisaac RJ, Jerums G, Weekes A, Moran J, Shaw JE, *et al*. Nonalbuminuric renal impairment in type 2 diabetic patients and in the general population (national evaluation of the frequency of renal impairment co-existing with

- 1
2
3 NIDDM [NEFRON] 11). *Diabetes Care* 2009;32:1497-1502.
- 4 41. Penno G, Solini A, Bonora E, Fondelli C, Orsi E, Zerbini G, *et al.* Clinical significance
5 of nonalbuminuric renal impairment in type 2 diabetes. *J Hypertens* 2011;29:1802-1809.
- 6 42. Yokoyama H, Sone H, Oishi M, Kawai K, Fukumoto Y, Kobayashi M, *et al.* Prevalence
7 of albuminuria and renal insufficiency and associated clinical factors in type 2 diabetes:
8 the Japan Diabetes Clinical Data Management study (JDDM15). *Nephrol Dial*
9 *Transplant* 2009;24:1212-1219.
- 10 43. Pugliese G, Solini A, Bonora E, Fondelli C, Orsi E, Nicolucci A, *et al.* Chronic kidney
11 disease in type 2 diabetes: lessons from the Renal Insufficiency And Cardiovascular
12 Events (RIACE) Italian Multicentre Study. *Nutr Metab Cardiovasc Dis*
13 2014;24:815-822.
- 14 44. Tanamas SK, Saulnier PJ, Fufaa GD, Wheelock KM, Weil EJ, Hanson RL, *et al.*
15 Long-term Effect of Losartan on Kidney Disease in American Indians With Type 2
16 Diabetes: A Follow-up Analysis of a Randomized Clinical Trial. *Diabetes Care*
17 2016;39:2004-2010.
- 18 45. Penno G, Solini A, Zoppini G, Orsi E, Zerbini G, Trevisan R, *et al.* Rate and
19 determinants of association between advanced retinopathy and chronic kidney disease in
20 patients with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events
21 (RIACE) Italian multicenter study. *Diabetes Care* 2012;35:2317-2323.
- 22 46. Rodriguez-Poncelas A, Mundet-Tuduri X, Miravet-Jimenez S, Casellas A, Barrot-De la
23 Puente JF, Franch-Nadal J, *et al.* Chronic Kidney Disease and Diabetic Retinopathy in
24 Patients with Type 2 Diabetes. *PLoS One* 2016;11:e0149448.
- 25 47. Ricardo AC, Grunwald JE, Parvathaneni S, Goodin S, Ching A, Lash JP. Retinopathy
26 and CKD as predictors of all-cause and cardiovascular mortality: National Health and
27 Nutrition Examination Survey (NHANES) 1988-1994. *Am J Kidney Dis*
28 2014;64:198-203.
- 29 48. Grunwald JE, Pistilli M, Ying GS, Maguire M, Daniel E, Whittock-Martin R, *et al.*
30 Retinopathy and the Risk of Cardiovascular Disease in Patients With Chronic Kidney
31 Disease (from the Chronic Renal Insufficiency Cohort Study). *Am J Cardiol*
32 2015;116:1527-1533.
- 33 49. Semeraro F, Cancarini A, dell'Omo R, Rezzola S, Romano MR, Costagliola C. Diabetic
34 Retinopathy: Vascular and Inflammatory Disease. *J Diabetes Res* 2015;2015:582060.
- 35 50. Chang HW, Li YH, Hsieh CH, Liu PY, Lin GM. Association of body mass index with
36 all-cause mortality in patients with diabetes: a systemic review and meta-analysis.
37 *Cardiovasc Diagn Ther* 2016;6:109-119.
- 38 51. Cea Soriano L, Johansson S, Stefansson B, Rodriguez LA. Cardiovascular events and
39 all-cause mortality in a cohort of 57,946 patients with type 2 diabetes: associations with
40 renal function and cardiovascular risk factors. *Cardiovasc Diabetol* 2015;14:38.
- 41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 52. Pugliese G, Solini A, Fondelli C, Trevisan R, Vedovato M, Nicolucci A, *et al.*
4 Reproducibility of albuminuria in type 2 diabetic subjects. Findings from the Renal
5 Insufficiency And Cardiovascular Events (RIACE) study. *Nephrol Dial Transplant*
6 2011;26:3950-3954.
7
8 53. Karoli R, Fatima J, Shukla V, Garg P, Ali A. Predictors of diabetic retinopathy in patients
9 with type 2 diabetes who have normoalbuminuria. *Ann Med Health Sci Res*
10 2013;3:536-540.
11
12 54. Yoon HE, Kim ES, Mo EY, Shin SJ, Moon SD, Han JH. High normal albuminuria is
13 associated with arterial stiffness and carotid atherosclerosis in Korean patients with type
14 2 diabetes. *Nutr Metab Cardiovasc Dis* 2015;25:787-794.
15
16 55. Salinero-Fort MA, San Andres-Rebollo FJ, de Burgos-Lunar C, Abanades-Herranz JC,
17 Carrillo-de-Santa-Pau E, Chico-Moraleja RM, *et al.* Cardiovascular and all-cause
18 mortality in patients with type 2 diabetes mellitus in the MADIABETES Cohort Study:
19 Association with chronic kidney disease. *J Diabetes Complications* 2016;30:227-236.
20
21 56. Chen LI, Guh JY, Wu KD, Chen YM, Kuo MC, Hwang SJ, *et al.* Modification of diet in
22 renal disease (MDRD) study and CKD epidemiology collaboration (CKD-EPI)
23 equations for Taiwanese adults. *PLoS One* 2014;9:e99645.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. The clinical data of patients according to the presence of CKD and DR

	CKD(-)DR(-) (n = 306)	CKD(-)DR(+) (n = 130)	CKD(+DR(-) (n = 149)	CKD(+DR(+) (n = 80)	P value
Age (years)	57 ± 15	62 ± 13	69 ± 10	70 ± 9	<0.001
Male, n (%)	189 (61.8%)	63 (48.5%)	82 (55.0%)	42 (52.5%)	0.057
BMI (kg/m ²)	23.7 ± 4.5	23.3 ± 4.0	24.2 ± 4.1	24.2 ± 4.3	0.367
Systolic blood pressure (mmHg)	124 ± 14	129 ± 15	127 ± 15	128 ± 14	0.004
Diastolic blood pressure (mmHg)	74 ± 11	75 ± 10	71 ± 9	72 ± 10	0.003
Diabetes duration (years) [#]	6.7 ± 6.7	11.4 ± 7.4	7.9 ± 7.7	13.2 ± 8.4	<0.001
Current smoker, n (%)	96 (31.4%)	36 (27.7%)	31 (20.8%)	13 (16.3%)	0.014
White blood cell count (10 ⁶ /L)	7836 ± 5193	7210 ± 2421	8258 ± 3504	8358 ± 3285	0.227
HbA1c (%)	11.5 ± 2.9	10.6 ± 2.3	10.4 ± 3.3	9.3 ± 2.6	<0.001
Total cholesterol (mmol/L)	4.8 ± 1.3	5.0 ± 1.3	4.6 ± 1.3	4.7 ± 1.5	0.197
Triglyceride (mmol/L) [#]	1.9 ± 1.9	1.9 ± 2.2	2.0 ± 2.2	1.8 ± 1.3	0.574
HDL cholesterol (mmol/L)	1.1 ± 0.4	1.1 ± 0.4	1.0 ± 0.3	1.0 ± 0.4	0.149
eGFR (mL/min/1.73m ²) [#]	88 ± 23	87 ± 20	45 ± 13	42 ± 15	<0.001
Hypertension, n (%)	171 (55.9%)	93 (71.5%)	113 (75.8%)	63 (78.8%)	<0.001
Antihypertensive agents, n (%)	91 (29.7%)	63 (48.5%)	90 (60.4%)	47 (58.8%)	<0.001
ACE inhibitor or ARB, n (%)	58 (19.0%)	44 (33.8%)	59 (39.6%)	32 (40.0%)	<0.001
α-blocker, n (%)	20 (6.5%)	14 (10.8%)	20 (13.4%)	10 (12.5%)	0.079
β-blocker, n (%)	20 (6.5%)	9 (6.9%)	3 (2.0%)	6 (7.5%)	0.172
Calcium channel blocker, n (%)	43 (14.1%)	28 (21.5%)	37 (24.8%)	20 (25.0%)	0.015
Diuretics, n (%)	8 (2.6%)	6 (4.6%)	11 (7.4%)	16 (20.0%)	<0.001
Oral antihyperglycemic drugs, n (%)	151 (49.3%)	65 (50.0%)	53 (35.6%)	27 (33.8%)	0.005
Insulin secretagogues, n (%)	127 (41.5%)	56 (43.1%)	46 (30.9%)	23 (28.8%)	0.027
Metformin, n (%)	95 (31.0%)	41 (31.5%)	26 (17.4%)	17 (21.3%)	0.007

1						
2	Thiazolidinediones, n (%)	6 (2.0%)	5 (3.8%)	2 (1.3%)	0 (0.0%)	0.230
3	α -glucosidase inhibitor, n (%)	10 (3.3%)	5 (3.8%)	3 (2.0%)	2 (2.5%)	0.811
4	Insulin therapy, n (%)	231 (75.5%)	80 (61.5%)	70 (47.0%)	38 (47.5%)	<0.001
5	Statins, n (%)	28 (9.2%)	12 (9.2%)	17 (11.4%)	12 (15.0%)	0.442
6						

7 ACE = angiotensin-converting enzyme, ARB = angiotensin II receptor antagonists, BMI = body mass index, CKD = chronic kidney disease, DR = diabetic retinopathy,
 8 HbA1c = glycated hemoglobin, HDL = high-density lipoprotein.

9 # Kruskal-Wallis tests to determine the significance of the differences due to skewed distribution in diabetic duration, triglycerides and eGFR

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

For peer review only

Table 2. Results of Cox regression analysis for the effects of risk factors on (A) all-cause and (B) cardiovascular mortality**(A) All-cause mortality**

	Univariate model			Multivariate model					
	Crude			Model 1			Model 2		
	HR	95%CI	P value	HR	95%CI	P value	HR	95%CI	P value
CKD(-)DR(-)*	1.000			1.000			1.000		
CKD(-)DR(+)	1.590	(1.179, 2.145)	0.002	1.556	(1.148, 2.108)	0.004	1.686	(1.202, 2.364)	0.002
CKD(+DR(-)	1.842	(1.377, 2.463)	<0.001	1.416	(1.042, 1.924)	0.026	1.381	(0.984, 1.939)	0.062
CKD(+DR(+)	2.791	(2.016, 3.866)	<0.001	2.209	(1.573, 3.101)	<0.001	2.263	(1.551, 3.302)	<0.001
Age (every 10 years)	1.455	(1.318, 1.607)	<0.001	1.328	(1.197, 1.472)	<0.001	1.325	(1.177, 1.491)	<0.001
Gender (male)	1.763	(1.394, 2.229)	<0.001	1.763	(1.388, 2.239)	<0.001	1.692	(1.298, 2.206)	<0.001
Current smoker (yes/no)	1.223	(0.958, 1.561)	0.107						
Diabetes duration >7 years (yes/no)	1.271	(1.012, 1.596)	0.039				1.084	(0.832, 1.412)	0.550
BMI (every 1 kg/m ²)	0.959	(0.931, 0.987)	0.004				0.954	(0.925, 0.984)	0.003
Systolic BP (every 10 mmHg)	1.081	(1.002, 1.167)	0.045				1.017	(0.932, 1.111)	0.701
HbA1c (every 1%)	0.969	(0.927, 1.013)	0.163						
Metformin (yes/no)	0.776	(0.604, 0.998)	0.049				0.751	(0.549, 1.028)	0.074
Insulin secretagogues (yes/no)	0.851	(0.677, 1.070)	0.167						
Insulin therapy (yes/no)	0.777	(0.619, 0.974)	0.029				1.094	(0.807, 1.483)	0.562
Statins (yes/no)	1.090	(0.763, 1.557)	0.635						
ACE inhibitor or ARB (yes/no)	1.144	(0.900, 1.454)	0.271						
Calcium channel blocker (yes/no)	1.237	(0.942, 1.625)	0.125						
Diuretics (yes/no)	2.517	(1.714, 3.696)	<0.001				1.765	(1.115, 2.793)	0.015

ACE = angiotensin-converting enzyme, ARB = angiotensin II receptor antagonists, BMI = body mass index, BP = blood pressure, HbA1c = glycated hemoglobin, CI = confidence interval, HR = hazard ratio

The risk factors in the univariate model were selected based on the findings in Table 1.

The risk factors in model 2 were selected based on the statistical significance indicated in the univariate model.

*the overall P value <0.001 among the CKD(-)DR(-), CKD(-)DR(+), CKD(+DR(-), CKD(+DR(+)) groups

(B) Cardiovascular mortality

	Univariate model			Multivariate model					
	Crude			Model 1			Model 2		
	HR	95%CI	P value	HR	95%CI	P value	HR	95%CI	P value
CKD(-)DR(-)*	1.000			1.000			1.000		
CKD(-)DR(+)	2.092	(1.340, 3.267)	0.001	2.039	(1.297, 3.203)	0.002	1.896	(1.153, 3.115)	0.012
CKD(+DR(-)	1.937	(1.221, 3.072)	0.005	1.387	(0.855, 2.251)	0.185	1.376	(0.815, 2.322)	0.232
CKD(+DR(+)	3.601	(2.215, 5.854)	<0.001	2.710	(1.634, 4.493)	<0.001	2.471	(1.421, 4.297)	0.001
Age (every 10 years)	1.615	(1.377, 1.894)	<0.001	1.445	(1.224, 1.706)	<0.001	1.389	(1.152, 1.674)	<0.001
Gender (male)	2.124	(1.472, 3.066)	<0.001	2.132	(1.465, 3.102)	<0.001	2.126	(1.391, 3.250)	<0.001
Current smoker (yes/no)	1.326	(0.922, 1.908)	0.128						
Diabetes duration >7 years (yes/no)	1.775	(1.237, 2.546)	0.002				1.196	(0.788, 1.815)	0.401
BMI (every 1 kg/m ²)	0.885	(0.843, 0.928)	<0.001				0.877	(0.836, 0.921)	<0.001
Systolic BP (every 10 mmHg)	1.157	(1.034, 1.295)	0.011				1.035	(0.912, 1.175)	0.593
HbA1c (every 1%)	0.977	(0.914, 1.045)	0.503						
Metformin (yes/no)	0.819	(0.562, 1.193)	0.297						
Insulin secretagogues (yes/no)	0.950	(0.675, 1.339)	0.771						
Insulin therapy (yes/no)	0.900	(0.635, 1.276)	0.554						
Statins (yes/no)	0.788	(0.425, 1.460)	0.448						
ACE inhibitor or ARB (yes/no)	1.572	(1.113, 2.221)	0.010				1.159	(0.765, 1.756)	0.487
Calcium channel blocker (yes/no)	1.366	(0.914, 2.041)	0.128						
Diuretics (yes/no)	2.387	(1.316, 4.330)	0.004				1.321	(0.618, 2.821)	0.473

ACE = angiotensin-converting enzyme, ARB = angiotensin II receptor antagonists, BMI = body mass index, BP = blood pressure, HbA1c = glycated hemoglobin, CI = confidence interval, HR = hazard ratio

The risk factors in the univariate model were selected based on the findings in Table 1.

The risk factors in model 2 were selected based on the statistical significance indicated in the univariate model.

*the overall P value <0.001 among the CKD(-)DR(-), CKD(-)DR(+), CKD(+DR(-), CKD(+DR(+)




Figure 1.
Flow diagram of enrollment of study subjects with normoalbuminuria.

210x297mm (300 x 300 DPI)





Figure 2.

Kaplan-Meier curves showing survival rates categorized according to chronic kidney disease (CKD) and diabetic retinopathy (DR) in type 2 diabetic inpatients with normoalbuminuria.

210x297mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Supplementary figure.
Receiver operating characteristic (ROC) analysis curves for differentiating normoalbuminuria (urine albumin excretion < 30 mg/day) based on daily urinary protein excretion.

210x297mm (300 x 300 DPI)

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cohort studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1,2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2,3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4,5
Objectives	3	State specific objectives, including any prespecified hypotheses	5
Methods			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	5
		(b) For matched studies, give matching criteria and number of exposed and unexposed	NA
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7
Bias	9	Describe any efforts to address potential sources of bias	14,15
Study size	10	Explain how the study size was arrived at	8
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	7,8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	7,8
		(b) Describe any methods used to examine subgroups and interactions	10
		(c) Explain how missing data were addressed	NA
		(d) If applicable, explain how loss to follow-up was addressed	NA
		(e) Describe any sensitivity analyses	8,9
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	9, Figure 2
		(b) Give reasons for non-participation at each stage	Figure 2
		(c) Consider use of a flow diagram	Figure 2
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Table 1
		(b) Indicate number of participants with missing data for each variable of interest	NA
		(c) Summarise follow-up time (eg, average and total amount)	9
Outcome data	15*	Report numbers of outcome events or summary measures over time	9,10, Figure 2
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Table 2
		(b) Report category boundaries when continuous variables were categorized	11
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	NA
Discussion			
Key results	18	Summarise key results with reference to study objectives	12
Limitations			
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	12-14
Generalisability	21	Discuss the generalisability (external validity) of the study results	12-14
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	14

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.